Screening of chemical libraries for new antifungal drugs against *Aspergillus fumigatus* reveals the potential mechanism of action of miltefosine

Thaila Fernanda dos Reis^{1,2}, Maria Augusta Crivelente Horta¹, Ana Cristina Colabardini¹, Caroline Mota Fernandes³, Lilian Pereira Silva¹, Rafael Wesley Bastos¹, Maria Vitória de Lazari Fonseca¹, Fang Wang⁴, Celso Martins⁵, Márcio L. Rodrigues^{6,7}, Cristina Silva Pereira⁵, Maurizio Del Poeta^{3,8,9,10}, Koon Ho Wong^{4,11,12} and Gustavo H. Goldman¹

¹Faculdade de Ciências Farmacêuticas de Ribeirão Preto, Universidade de São Paulo, Ribeirão Preto, Brazil;

²MicroControl Innovation Ltda, Ribeirão Preto, São Paulo, Brazil

³Department of Microbiology and Immunology, Stony Brook University, Stony Brook, New York, USA;

⁴Faculty of Health Sciences, University of Macau, Macau SAR of China;

⁵Instituto de Tecnologia Química e Biológica António Xavier, Universidade Nova de Lisboa (ITQB NOVA), Oeiras, Portugal;

⁶Instituto Carlos Chagas (ICC), Fundação Oswaldo Cruz – Fiocruz, Curitiba/PR, Brazil;

⁷Instituto de Microbiologia Paulo de Góes, Universidade Federal do Rio de Janeiro (UFRJ), Rio de Janeiro/RJ, Brazil;

⁸Veteran Administration Medical Center, Northport, New York, USA;

⁹MicroRid Technologies Inc., 86 Deer Park Road, Dix Hills, New York, USA;

¹⁰Division of Infectious Diseases, School of Medicine, Stony Brook University, New York, USA

¹¹Institute of Translational Medicine, Faculty of Health Sciences, University of Macau, Avenida da Universidade, Taipa, Macau SAR of China;

¹²MoE Frontiers Science Center for Precision Oncology, University of Macau.

Keywords: *Aspergillus fumigatus*, drug repurposing, miltefosine, sphingolipids, transcription factor

35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68

Corresponding author: Dr. Gustavo H. Goldman
Departamento de Ciências Farmacêuticas
Faculdade de Ciências Farmacêuticas de Ribeirão
Preto, Universidade de São Paulo, Av. do Café S/N,
CEP 14040-903, Ribeirão Preto, São Paulo, Brazil,
Phone/Fax: 55-16-33154280/81, e-mail address:
ggoldman@usp.br

Abstract

Aspergillus fumigatus is an important fungal pathogen and the main etiological agent of aspergillosis, a disease characterized by a noninvasive process that can evolve to a more severe clinical manifestation called invasive pulmonary aspergillosis (IPA) in immunocompromised patients. The antifungal arsenal to threat aspergillosis is very restricted. Azoles are the main therapeutic approach to control IPA, but the emergence of azole-resistant *A. fumigatus* isolates has significantly increased over the last decades. Therefore, new strategies are necessary to combat aspergillosis and drug repurposing has emerged as an efficient and alternative approach for identifying new antifungal drugs. Here, we used a screening approach to analyze *A. fumigatus* in vitro susceptibility to 1,127 compounds. *A. fumigatus* was more susceptible to 10 compounds, including miltefosine, a drug that displayed fungicidal activity against *A. fumigatus*. By screening an *A. fumigatus* transcription factor null library, we identified a single mutant, which has the *rmiA* (resistant to miltefosine) gene deleted, conferring a phenotype of susceptibility to miltefosine. The transcriptional profiling (RNA-seq) of the wild-type and the $\Delta rmiA$ strains and the Chromatin Immunoprecipitation coupled to next generation sequencing (ChIP-Seq) of a RmiA-tagged strain exposed to miltefosine revealed genes of the sphingolipids pathway that are directly or indirectly regulated by RmiA. Sphingolipids analysis demonstrated that the mutant has overall decreased levels of sphingolipids when growing in the presence of miltefosine. The identification of RmiA represents the first genetic element described and characterized which plays a direct role in miltefosine response in fungi.

Author summary

The filamentous fungus *Aspergillus fumigatus* causes a group of diseases named aspergillosis and their development occurs after the inhalation of conidia dispersed in the environment. Very few classes of antifungal drugs are available for aspergillosis treatment, e.g., azoles, but the emergence of global resistance to azoles in *A. fumigatus* clinical isolates has increased over the last decades. Repositioning or repurposing drugs already available on the market is an interesting and faster opportunity for the identification of novel antifungals agents. By using a repurposing strategy, we identified 10 different compounds that impact *A. fumigatus* survival. One of these compounds, miltefosine, demonstrated fungicidal activity against *A. fumigatus*. The mechanism of action of miltefosine is unknown and aiming to get more insights about it, we identified a transcription factor RmiA (Resistant to miltefosine) important for miltefosine resistance. Our results suggest that miltefosine plays antifungal activity against *A. fumigatus* interfering in the sphingolipids biosynthesis.

Introduction

Fungi are widespread in nature surviving as saprophytic organisms or associated with animals and plants where they can behave as commensal or opportunistic organisms. In humans, pathogenic fungi can cause both superficial and invasive infections giving rise to the death of millions of people annually (1–3). *Cryptococcus*, *Candida*, *Aspergillus*, and *Pneumocystis spp* are responsible for the most representative invasive fungal infections (1) showing death rates as high as tuberculosis and malaria (2, 4, 5). The levels of mortality are dependent on the host immune system integrity, being particularly important for immunocompromised patients (6–8). These individuals comprise a risk group that is expanding quickly due to the increasing number of immune-deficient patients who underwent transplant or chemotherapy, and patients under therapy with high dosage of corticosteroids (9–11).

Aspergillus spp. cause a group of diseases collectively named aspergillosis and their development occur after the inhalation of conidia dispersed in the environment (12). In immunocompetent patients the development of aspergillosis is mainly characterized by noninvasive diseases including aspergilloma, chronic necrotizing pulmonary aspergillosis, chronic cavitary pulmonary aspergillosis, and chronic fibrotic pulmonary aspergillosis, which are together defined as chronic pulmonary aspergillosis (12–16). These diseases present different manifestations but are in general related to a preexisting cavitary lung disease and classical features of systemic fungal disease are always absent (17, 18). Additionally, the allergic bronchopulmonary aspergillosis (ABPA) is a severe atopic disease caused by *Aspergillus*, mainly *A. fumigatus* (19, 20). The disease originates from the sensitization to fungal allergens of the host who present high levels of IgE (21). Patients with cystic fibrosis and other genetic diseases that affect the respiratory system are more predisposed to ABPA (19, 22, 23). Finally, the invasive pulmonary aspergillosis (IPA) is an important clinical manifestation caused by *Aspergillus spp.* presenting high levels of mortality in immunocompromised patients (1, 24). IPA is the most common invasive fungal infection in recipients of both hematopoietic stem cells and solid-organ transplants (1, 24). In this group of high-risk patients for IPA, *A. fumigatus*

represents the major cause of the disease reaching up to 90% of mortality (9–12, 25).

Very few classes of antifungal drugs are available for IPA treatment, such as polyenes (amphotericin B), azoles (itraconazole, posaconazole, voriconazole, and isavuconazole), and echinocandins (caspofungin) (26–29). Although both amphotericin B and echinocandins can be used to treat IPA, these drugs have clinical limitations. Amphotericin B shows high levels of nephrotoxicity and side effects while echinocandins are not fully recommended as monotherapy for IPA (9, 13, 30–32). So far, the administration of triazoles is the first therapeutic approach applied to control *A. fumigatus* infections showing the most prominent usage in the medical field (13, 33). Among them, itraconazole (introduced in 1990s), voriconazole (introduced in 2002) and posaconazole (introduced in 2006) are the most common drugs utilized for the treatment of aspergillosis (34). Voriconazole is the primary treatment against IPA followed by liposomal amphotericin B (L-AMB) and echinocandins, which are recommended as a second line therapy (35) (13, 33). Moreover, the activity of isavuconazole, a new extended-spectrum triazole drug, has been recently tested against *Aspergillus* (36–39).

The number of azole-resistant *A. fumigatus* clinical isolates has dramatically increased over the last decades has become a major concern (35, 40–45). Additionally, azoles are also used in the agriculture to combat plant pathogenic fungi and recently, its usage for agricultural purposes has been linked to the emergence of azole-resistant isolates among human fungal pathogens (40, 46–49). Therefore, the emergence of global resistance to currently available antifungals agents represent a significant threat to immunosuppressed patients, as the current arsenal of antifungal drugs is very limited.

A. fumigatus has developed different azole resistance mechanisms, e.g. amplification of the gene encoding the drug target, Cyp51/Erg11 14- α demethylase; drug target modification, and/or overexpression of efflux pumps (50–54). Specifically, These events are linked to amino acid substitution(s) in the target Cyp51A protein, tandem repeat sequence insertions at the *cyp51A* promoter, and overexpression of the ABC transporter Cdr1B (55–57). The scenario became even more dramatic since the emergence of fungal isolates intrinsically resistant to other commercial antifungals available. For instance,

Some clinical isolates of *A. flavus* and *A. terreus*, also responsible for cases of IPA, have been reported as intrinsically resistant to amphotericin B (12, 29, 58–61).

This situation highlights the need to understand the mechanisms of drug resistance and tolerance, and the search for novel antifungal agents (62, 63). As a few antifungal compounds are coming to market because their development is time-consuming and expensive, repositioning or repurposing drugs which are already licensed is an interesting and faster opportunity for the identification of novel antifungals agents (64–66). By using the repurposing strategy, many compounds have already been identified as new potential drugs against several diseases including parasitosis, protozooses and mycoses (64, 66–71). Here, screened two compound collection to analyze *A. fumigatus* *in vitro* susceptibility for compounds present in two compound libraries. The first library has active compounds against neglected diseases (The Pathogen Box) while the second one includes drugs previously approved for usage against human diseases [National Institutes of Health (NIH) clinical collection (NCC)]. We showed here that *A. fumigatus* was susceptible to at least 10 different compounds from the two libraries. One of these compounds, miltefosine, a drug mainly used in the treatment of visceral and cutaneous leishmaniasis (72, 73), demonstrated fungicidal activity against *A. fumigatus*. Aiming to get more insights about the mechanism of action of miltefosine, we screened an *A. fumigatus* transcription factor null mutant library (484 null mutants) and identified a single mutant highly sensitive to miltefosine. The gene deleted in this mutant was named *rmiA* (resistant to miltefosine). A combination of RNA seq transcriptome and Chromatin Immunoprecipitation (ChIP) coupled to next generation sequencing (Seq) studies revealed differentially expressed genes directly or indirectly regulated by RmiA. The sphingolipids profiling of the wild-type and the $\Delta rmiA$ strains exposed to miltefosine revealed that the mutant has overall lower levels of sphingolipids comparing to the wild-type. Our results suggest that miltefosine plays antifungal activity against *A. fumigatus* by directly interfering in the sphingolipids biosynthetic pathway.

Results

Screening of the Pathogen Box and NIH Clinical Library. In order to find known compounds that are active against *A. fumigatus*, we tested its susceptibility to two chemical drug libraries, (i) the Pathogen Box (containing 400 compounds, see <https://www.mmv.org/mmv-org>) and the National Institutes of Health (NIH) clinical collection (NCC) (containing 727 compounds; see <https://pubchem.ncbi.nlm.nih.gov/source/NIH%20Clinical%20Collection>) through Minimal Inhibitory Concentration (MIC) assays. In total, combining both libraries 1,127 compounds were assessed by using MIC values up to 25 μ M. *A. fumigatus* was susceptible to four known antifungal agents present in these collections (posaconazole, difenoconazole, bitertanol and amphotericin B; MIC values 5 μ M, 5 μ M, 5 μ M and 10 μ M, respectively). These results supported the reliability of the screening approach. *A. fumigatus* was also susceptible to other compounds with MIC values ranging from 1.56 to 25 μ M (Table 1). In Table 1, we describe the compound name, the MIC detected in our screening, the current usage purpose (Description) and the mode of action (if known) for the 10 compounds (Table 1). These compounds include: (i) two azole salts, econazole and oxiconazole, expected to inhibit to some extent *A. fumigatus* growth, (ii) fluvastatin, a statin drug class used for hypercholesterolemia treatment, (iii) mesoridazine, a piperidine neuroleptic drug, (iv) cisapride, a parasympathomimetic drug acting as a serotonin 5-HT₄ agonist, (v) indinavir sulfate, a protease inhibitor used in anti-HIV cocktails, (vi) enalaprilat, an angiotensin-converting enzyme inhibitor, (vii) vincristine sulfate, an inhibitor of microtubule formation in the mitotic spindle, (viii) iodoquinol, an anti-amoebiasis agent with unknown mechanism of action and (ix) miltefosine, an anti-Leishmania compound with unknown mechanism of action (Table 1).

To determine if these compounds are fungicidal or fungistatic, the *A. fumigatus* conidial viability was tested after 48 h of exposure to each compound at its corresponding MIC (Figure 1A). Five compounds (fluvastatin, cisapride, indinavir sulphate, vincristine sulphate, and miltefosine) had 100 % fungicidal while six had fungistatic mechanism of action with 80 to 95 % of conidial killing at MIC concentration (Figure 1A).

These results suggest that some of these compounds are fungicidal and can act directly in specific *A. fumigatus* cell targets while others (like cisapride and enalaprilat) could be a lead compound in antifungal drug discovery.

Miltefosine displays antagonistic interaction with myriocin, a sphingosine biosynthesis inhibitor. We decided to investigate miltefosine in more detail because it is a fungicidal drug with an unknown mechanism of action. The combination between drugs is commonly used in clinical practice aiming to potentialize the antifungal effect of the drugs (74). Furthermore, the combination assay can help unraveling the mechanism of action of the drugs and how this may vary according to the concentration (75). To check if miltefosine has any interaction with other antifungal drugs, we combined this compound (ranging from 0.001 to 8.0 µg/ml, MIC value of 10 µM corresponds to 4 µg/ml) with different antifungal drugs (Figures 1B to 1E). Miltefosine was combined with posaconazole [0.03 - 2.0 µg/ml], voriconazole [0.0007 - 0.5 µg/ml], amphotericin B [0.06 - 4.0 µg/ml] and caspofungin [4.0 - 256.0 µg/ml] (Figures 1B to 1E). Using the checkerboard microdilution method, the interaction between miltefosine and the other compounds was determined through the fractional inhibitory concentration index (FICI). The interaction between the drugs was classified as synergic ($FICI \leq 0.5$), indifferent ($0.5 < FICI \leq 4.0$) or antagonic ($FICI > 4.0$) (76). Under the assayed conditions, the FICI index varied from 1- 2.5 in the combination of voriconazole and miltefosine, 1- 0.6 between posaconazole and miltefosine, 0.6 – 1.2 between amphotericin B and miltefosine and 1.0 -1.1 between caspofungin and miltefosine. These data show that the addition of miltefosine did not affect the antifungal effects of the tested clinical antifungals against *A. fumigatus* indicating that there is no interaction between them.

There are evidences in the literature showing that miltefosine can affect the sphingolipid metabolism in trypanosomatids (77, 78). To check if miltefosine could display any interaction with drugs that affect the cellular lipids biosynthesis, we combined different concentrations of miltefosine [0.001 to 8.0 µg/ml] and myriocin [2.0 – 128 µg/ml] (Figure 1F), an inhibitor of serine palmitoyltransferase, the first step in sphingosine biosynthesis (79). At low concentrations of the drugs, indifferent interaction was observed. Interestingly, at high concentrations, myriocin impaired the antifungal effects of miltefosine against *A. fumigatus*

demonstrating an antagonistic effect between these compounds (Figure 1F). Considering that myriocin has only one single target identified, this result may suggest that exist a component of the sphingolipid pathway important to the antifungal effect of miltefosine.

RmiA is the major transcription factor that mediates miltefosine response in *A. fumigatus*.

To assess if there are transcriptional programs modulating the tolerance response to miltefosine, a library of 484 *A. fumigatus* transcription factor (TF) null mutants (80) was screened for sensitivity to miltefosine [0.001 to 8.0 µg/ml]. A primary screening using 96-well plates identified six TF null mutants with different susceptibilities to miltefosine. To validate the differential susceptibility of these mutants to miltefosine, the 6 TF null mutants were grown in the absence or presence of different miltefosine concentrations, and their radial growth were measured (Figure 2). When compared to the wild-type strain, we observed discrete differences in five of these mutant strains (Figure 2). The $\Delta mcnB$ (AFUA_5G05600 that encodes a homologue of *A. nidulans* McnB, a multicopy supressor of *A. nidulans nimA1*, (81) showed about 20 % growth inhibition (Figures 2A and 2B) while $\Delta pacC$ (AFUA_3G11970 that encodes PacC, a protein important for pH regulation (82) showed about 50 % inhibition compared to the wild-type strain at 8 µg/ml (Figure 2A and 2B). The $\Delta ssIA$ (AFUA_5G04333 that encodes a homologue of *Saccharomyces cerevisiae* Ssl1p, a subunit of the general transcription factor TFIIH) has about 50 % growth inhibition compared to the wild-type strain at 8 µg/ml (Figures 2A and 2B). The $\Delta sebA$ (AFUA_4G09080 encodes a TF important to cope with different kinds of stress (83) showed a 40 % inhibition to miltefosine 8 µg/ml while the wild-type is inhibited 60 % at this concentration (Figures 2A and 2B). The AFUA_5G03030 null mutant has 65 % growth inhibition compared to the wild-type strain at miltefosine 8 µg/ml (Figure 2). Notably, the AFUA_2G12070 mutant was unable to grow at 4 µg/ml miltefosine (Figures 2A, 2B, 3A and 3B). AFUA_2G12070 encodes a 492 amino acids novel fungal Zn₂-Cys₆ transcription factor (<http://pfam.xfam.org/family/PF00172#Zn2/Cys6>). We named this gene *rmiA* (resistant to miltefosine). The $\Delta rmiA$ was complemented and the complementing strain $\Delta rmiA:rmiA^+$ presented a reversible phenotype in terms of miltefosine sensitivity indicating that the miltefosine sensitivity phenotype of $\Delta rmiA$ is due to

the specific deletion of the *rmiA* gene (Figures 3A and 3B). The $\Delta rmiA$ mutant has no differential susceptibility to different stressing conditions such as growth on increasing concentrations of NaCl, Calcofluor white, sorbitol, CaCl₂ and menadione (Supplementary Figure S1).

Aiming to localize the RmiA, we constructed a functional C-terminal RmiA:GFP strain (Supplementary Figure S2) that showed no fluorescence in the absence of miltefosine (Figures 3C and 3D). However, when the RmiA:GFP strain was shifted 15 minutes to MM supplemented with 3 μ g/ml of miltefosine, RmiA:GFP can be detected in about 50 % of the nuclei (Figures 3C and 3D). In addition, we also constructed a functional RmiA:3xHA strain (Supplementary Figure S2). This strain was grown in VMM and further exposed to RPMI supplemented (or not) to an inhibitory concentration of miltefosine (12.5 μ g/ml) for 4 and 8 min. A very faint band of 54.3 kDa corresponding to RmiA:3xHA was observed in the control not exposed to miltefosine while increased intensity bands were observed in 4 and 8 h exposure to miltefosine (Figure 3E).

These results indicate that the RmiA protein quickly translocates to the nucleus and its expression is also increased upon miltefosine exposure.

Miltefosine induces necrosis-like cell death and increases mitochondrial fragmentation in *A. fumigatus*. *A. fumigatus* form mitochondrial tubular and highly dynamic networks that are fragmented in the presence of antifungal and oxidative stressing agents such as hydrogen peroxide (84, 85). This increased mitochondrial fragmentation has been associated as a marker for cell death (85). Propidium Iodide (PI) is a fluorescent DNA-binding dye that freely penetrates cell membranes of dead or dying cells, but is excluded from viable cells. Late apoptosis and early necrosis is characterized by an increased number of PI-positive cells. To evaluate the effects of miltefosine and PI on the mitochondrial morphology and viability, germlings from the wild-type, $\Delta rmiA$ and $\Delta rmiA::rmiA^+$ strains were treated with 3 μ g/ml of the drug for 0, 5 or 10 min and green MitoTracker (a mitochondrial fluorescent probe) or PI were added and further analyzed by fluorescent microscopy (Figure 4A). In the absence of miltefosine an intact mitochondrial network was observed in all the three strains. However, upon 5 minutes of miltefosine exposure, the $\Delta rmiA$ cells showed about 60% of mitochondrial fragmentation evidenced by the presence of a punctuated

fluorescent pattern observed in the cytoplasm of the cells (Figures 4A and 4B), while in the wild-type and complemented strains the levels of mitochondrial fragmentation were much lower, 20 and 30 %, respectively (Figures 4A and 4B). When the wild-type and the $\Delta rmiA::rmiA^+$ germlings were left unexposed to miltefosine, about 5% of cells were stained by PI while in the $\Delta rmiA$ strain this level was about 7% (Figure 4C). However, upon miltefosine addition, the wild-type and the $\Delta rmiA::rmiA^+$ germlings were about 12% stained by PI (Figure 4C)., while more than 50% of the $\Delta rmiA$ germlings showed PI staining (Figure 4C). These results suggest that miltefosine induces both mitochondrial fragmentation and necrosis cell death in *A. fumigatus*., which was accentuated in $\Delta rmiA$, emphasizing the importance of RmiA for survival and viability of *A. fumigatus*.

A. fumigatus germlings were exposed to 4 µg/ml of a functional fluorescent analogue of miltefosine, MT-11C-BDP [11-(4,4-Difluoro-1,3,5,7-tetrametil-4-bora-3a,4a-diaza-s-indacen-2-il) n-undecilfosfatidilcolina] (86) for about 5 minutes (Figure 5). MT-11C-BDP localizes to tubular structures that resemble mitochondrial networks and that were also fragmented in a fraction of the germlings (Figures 5A and 5B). Colocalization with MitoTracker™ Deep Red FM indicated that MT-11C-BDP analogue is mainly localized at the mitochondria.

Miltefosine induces the modulation of genes encoding proteins responsible for the metabolism of lipids, fatty acid and derivatives. Aiming to get insights about genes that are modulated under miltefosine exposure, we carried out a transcriptomic analysis (RNA-seq) comparing *A. fumigatus* wild-type strain exposed to miltefosine. In comparison to the wild-type grown in MM, when the cells were shifted to RPMI medium supplemented with 3 µg/ml of miltefosine for 30 minutes, a total of 1,248 genes were upregulated ($\log_2FC > 1.0$; $P < 0.005$) and 940 genes were downregulated ($\log_2FC < -1.0$; $P < 0.005$). In both cases the false-discovery rate (FDR) was less than 0.05 (Supplementary Table S1).

The enrichment analysis using FunCat (<https://elbe.hki-jena.de/fungifun/fungifun.php>) showed a transcriptional upregulation of genes involved in vesicular and vacuolar transport, metabolism of glutamate, caspase activation, ABC transporters, osmosensing response, transport ATPases, stress response, proteasomal degradation, lipid transport and a high enrichment in lipid,

fatty acid, and isoprenoid metabolism (Figure 6A). Genes involved in nuclear transport, RNA transport, Mitochondrial transport, TCA cycle, nucleotide binding, unfolded protein response, aminoacyl-tRNA-synthetases, amino acid metabolism, rRNA processing, ribosome biogenesis and translation were downregulated upon miltefosine exposure (Figure 6A). These results suggest that under miltefosine treatment, *A. fumigatus* increases the expression of genes involved in fatty acid metabolism and transport, stress responses and specific transporters while represses mitochondrial functions (e.g. TCA cycle and mitochondrial transport) and amino acid and protein biosynthesis.

The *rmiA* is important for the induction of genes involved in lipid metabolism upon miltefosine exposure in *A. fumigatus*. To identify potential targets modulated by RmiA we performed the transcriptional profiling of the $\Delta rmiA$ null mutant under the same experimental design previously described for the wild-type strain. We identified 292 differentially expressed genes (DEGs), with 184 genes upregulated ($\log_2FC > 1.0$; $P < 0.005$) and 108 genes downregulated ($\log_2FC < -1.0$; $P < 0.005$; $FDR < 0.05$), upon miltefosine exposure (Supplementary Table S2). FunCat enrichment analysis has not shown categories for upregulated genes in the $\Delta rmiA$ mutant. However, FunCat for the downregulated genes in the $\Delta rmiA$ mutant exposed to miltefosine revealed enrichment for categories of genes encoding proteins involved in lipid, fatty acid and isoprenoid metabolism, NAD/NADP binding, homeostasis of protons, ribosomal proteins, electron transport and transport ATPases (Figure 6B).

A visual inspection of DEGs in both wild-type and $\Delta rmiA$ strains showed zinc finger proteins (AFUA_5G12760 and AFUA_6g02690), MFS transporters (AFUA_5G09780 and AFUA_7G01790) and a sensor histidine kinase regulator (AFUA_5G10020) with higher levels of expression in the $\Delta rmiA$ in comparison to the wild-type (Figure 6C). Genes involved in the metabolism of fatty acids (AFUA_4G00340, AFUA_2G12530, AFUA_6G07270, AFUA_5G10670, AFUA_8g02590), cytochrome P450 enzymes (AFUA_3g03930, AFUA_4G03800, AFUA_2G04290), cell division control protein (AFUA_2G17110), aldehyde dehydrogenase (AFUA_4G13500), isocitrate lyase (AFUA_4G13510) were downregulated in the $\Delta rmiA$ when compared to the wild-type strain (Figure 6C). Accordingly, the RNAseq data was validated by

performing real-time PCR on 3 selected genes that showed a very similar expression pattern in comparison with data from the RNAseq (Figure 6D).

Taken together our data shows that in the wild-type strain, the lipid and fatty acid metabolism are upregulated upon miltefosine exposure suggesting their possible importance for survival in presence of this drug. On the other hand, the deletion of *rmiA* gene leads to a deficiency in the lipid and fatty acid metabolism, strongly suggesting that it could be linked to the higher sensitivity of this mutant to miltefosine.

RmiA binds to a discrete number of gene promoter regions specifically in the presence of miltefosine.

Considering that RmiA seems to be a TF involved in miltefosine resistance in *A. fumigatus*, we decided to identify potential direct targets under RmiA control of this protein using the Chromatin Immunoprecipitation coupled to DNA sequencing (ChIP-seq) approach. The RmiA:3xHA strain (Supplementary Figure S2 and Figure 7A) was grown in MM and further exposed to RPMI supplemented (or not) with miltefosine for 30 min. After immune-precipitation using anti-HA antibody, samples were sequenced using the Illumina HiSeq2500 platform, the reads were aligned to the *A. fumigatus* Af293 reference strain and the program MACS2 was used for peak calling. The peak intensity map showed that RmiA binding was enriched at the promoter region of 12 specific genes which are present in different chromosomes: (i) AFUA_2G08260 encoding a homologue of *S. cerevisiae* Oye2p, a NADPH oxidoreductase containing flavin mononucleotide (FMN) that may be involved in sterol metabolism, oxidative stress response, and programmed cell death (www.yeastgenome.org), (ii) AFUA_3G03230 encoding a BZIP transcription factor (www.fungidb.org), (iii) AFUA_3G07300 AtrA encoding an ABC multidrug transporter (www.fungidb.org), (iv) AFUA_3G10770 encoding a homologue of *S. cerevisiae* Rbs1p, a sphingoid long-chain base (LCB) efflux transporter; integral membrane transporter that localizes to the plasma membrane and may transport long chain bases (LCBs) from the cytoplasmic side toward the extracytoplasmic side of the membrane; role in glycerophospholipid translocation (www.yeastgenome.org), (v) AFUA_4G03800 encoding a cytochrome P450 alkane hydroxylase (www.fungidb.org), (vi) AFUA_4G13500 encoding a homologue of *S. cerevisiae* Hfd1p, a dehydrogenase involved in ubiquinone and

sphingolipid metabolism, converting hexadecenal to hexadecenoic acid in sphingosine 1-phosphate catabolism, the human homologue of ALDH3A2, mutated in Sjogren-Larsson syndrome (www.yeastgenome.org and (87), (vii) AFUA_5G10670 encoding a protein that has domain(s) with predicted iron ion binding, oxidoreductase activity and role in fatty acid biosynthetic process, oxidation-reduction process (www.fungidb.org), (viii) AFUA_2G14410 encoding an orthologue that has a role in xanthophyll metabolic process (www.fungidb.org), (ix) AFUA_4G11270 encoding an unknown function hypothetical protein (www.fungidb.org), (x) AFUA_4G11280 encoding an orthologue that has dolichyl-phosphate-mannose-glycolipid alpha-mannosyltransferase activity and role in GPI anchor biosynthetic process (www.fungidb.org), (xi) AFUA_5G10660 encoding a pentatricopeptide repeat protein (www.fungidb.org), and (xii) AFUA_6G03320 encoding a MFS transporter (www.fungidb.org) (Figure 7A and Supplementary Table S3). The RmiA binding to these promoter regions happens specifically in presence of miltefosine suggesting that RmiA is important for the activity of those genes in the presence of this drug. Accordingly, the RNAseq data demonstrate that the expression levels of AFUA_2G08260, AFUA_3G03230, AFUA_3G07300, AFUA_3G10770, AFUA_4G03800, AFUA_4G13500, and AFUA_5G10670 are repressed in the $\Delta rmiA$ strain in comparison with the wild-type when both strains are exposed to miltefosine (Figure 7B and Supplementary Table S3).

To identify putative RmiA-binding motifs in *A. fumigatus*, we carried out Multiple Expectation maximum for Motif Elicitation (MEME) of the 500 nucleotides surrounding each peak sequence identified in the ChIP-seq. The results show the enrichment of two consensus DNA binding sequences for RmiA in the presence of miltefosine (Figure 7C). Two binding motifs were predicted: 5'-CGGAG(G or C)AA-3' (e-value of 5e-02) and 5'-AACNGAATGA-3' (e-value of 3.8e-02).

Together, our data highlight the importance of RmiA for events involved with the miltefosine resistance process in *A. fumigatus* and suggest that genes potentially modulated by the RmiA binding have specific binding motifs for this protein. Several promoter regions of genes that are bound by RmiA encode proteins involved in lipid metabolism.

RmiA is important for sphingolipids biosynthesis. Our previous results suggest that myriocin, a sphingolipid (SL) inhibitor, impairs the antifungal activity of miltefosine (Figure 1F). Considering that the metabolism of lipids seems to be involved with miltefosine resistance and the TF RmiA is linked to this process, we performed the SLs profiling of both wild-type and $\Delta rmiA$ strains exposed to miltefosine. Both strains were grown in VMM for 16h and shifted to RPMI media supplemented (or not) with 3 μ g/ml of miltefosine for 4h. The main SL intermediates starting from the branching point of the pathway (DHS; dihydrosphingosine) were then measured through mass spectrometry analysis and the results were expressed in fold increase or decrease compared to the control not exposed to miltefosine (Figure 8A).

The deletion of *rmiA* leads to an overall reduction of the analysed SLs when compared to the SL levels in the wild-type strain under the same conditions (Figure 8A). Interestingly, the reduction in SL levels occurs in both, acidic and neutral branches of the pathway, suggesting the deletion of *rmiA* affects the early steps of the SL biosynthetic process. The branching point of the SL pathway is DHS, the precursor of dihydroceramide (DHC; the first intermediary of the neutral branch) and the phytosphingosine (PHS; the first intermediary of the acidic branch). However, the DHS is also converted to dihydrosphingosine 1-phosphate (DHS-1P) starting the metabolic pathway where the DHS-1P is converted to glycerolipid through many enzymatic reactions (Figure 8A). Upon miltefosine exposure, there is an increase of DHS and a decrease in DHS-1P in the wild-type strain while the opposite is observed in the $\Delta rmiA$ mutant (Figure 8A). Phytosphingosine (PHS), ceramide (CER), hydroxyceramide (OH-CER), phosphoceramide (P-CER), hydroxyphosphoceramide (OH-PCER), glucoceramide (GLC-CER), and inositolphosphoryl-ceramide (IPC) are increased when the wild-type strain is exposed to miltefosine (Figure 8A). In contrast, all these sphingolipids were reduced in the $\Delta rmiA$ when exposed to miltefosine (Figure 8A). We investigated in our RNA seq dataset the expression levels of the genes that encode enzymes involved in the different steps of the SLs pathway (Figure 8B). We observed 5 genes (Lcb2, AFUA_1G11890; LagA, AFUA_6G10460; Sur2, AFUA_1G16850; and LagA, AFUA_6G10460) with reduced and 2 genes (AurA, AFUA_3G09960 and MitA, AFUA_6G04680) with increased expression when the wild-type was exposed to miltefosine (Figure 8B).

Interestingly, only one gene (Hfd1, AFUA_4G13500) is differentially expressed with reduced expression when the $\Delta rmiA$ mutant is exposed to miltefosine (Figure 8B). Taken together, our results suggest that miltefosine antifungal activity against *A. fumigatus* interferes directly in the SL biosynthesis pathway.

Azole-resistant clinical isolates of *A. fumigatus* are sensitive to miltefosine.

to verify if miltefosine is a good candidate for therapy against azole resistant strains, we tested if miltefosine could inhibit *A. fumigatus* growth of 19 clinical isolates (in addition to CEA17 strain) with different levels of azole resistance by determining their MICs. We tested 9 azole-sensitive *A. fumigatus* strains (CEA17, CYP15-109, IF1S-F4, IFM59056, ISFT-021, IFM61407, MO68507, MO54056, and IFM59056) and also 10 azole-resistant isolates, with different resistance mechanisms, cultured from different sample sites from patients from Portugal, Japan, Belgium and Switzerland (88) (Table 2). The most common azole-resistance mechanisms include amino acid substitutions in the target Cyp51A protein and tandem repeat sequence insertions at the *cyp51A* promoter (54) The *cyp51A* gene is not mutated in the azole-resistant strains F16134, F14946, CYP15-117, CYP15-147, CYP15-75, CYP15-93, CYP15-106, and CYP15-115 (*cyp51A* was not sequenced in the CYP-15-91 strain), suggesting different mechanisms of azole resistance (88). In contrast, strains 1799392 and 20089320 have TR34 tandem repeats at the *cyp51A* promoter region and L98H amino acid replacement at the Cyp51A (89). All the azole-sensitive or –resistant clinical isolates have a MIC of 4 μ g/ml of miltefosine (Table 2). These results strongly indicate that miltefosine can inhibit the growth of clinical isolates that have developed resistance to azoles through different mechanisms.

Miltefosine increases the survival of *Galleria mellonella* larvae infected with

***A. fumigatus*.** On the basis of its essential role in sphingolipid biosynthesis, we asked whether RmiA is important for *A. fumigatus* virulence. *G. mellonella* larvae (n = 10 for each strain) were infected with the wild-type, *rmiA* deletion and complementation strains, and survival was assessed over a time period of 10 days (Figure 9A). The wild-type, $\Delta rmiA$, and $\Delta rmiA::rmiA^+$ strains caused 90 to 100 % mortality after 9 to 10 days postinfection (p.i.) ($P < 0.001$, Figure 9A).

These results indicate that RmiA is not a key regulator of *A. fumigatus* pathogenesis in the *G. mellonella* model.

As a proof-of-principle of the *in vivo* antifungal activity of miltefosine, we tested its ability to control or reduce the *A. fumigatus* infection in *G. mellonella* larvae (Figures 9B and 9C). First, we tested three different concentrations of miltefosine (40, 60 and 80 mg/kg of the larva) aiming to verify the drug concentration that could cause minimal damage to the larvae. These miltefosine concentrations caused about 40 % mortality after 10 days ($P < 0.001$, Figure 9B). *A. fumigatus* infection of *G. mellonella* larvae combined with the different miltefosine concentrations resulted in about 50 % survival of the invertebrate host ($P < 0.001$, Figure 9C). These results indicate that miltefosine is able to control 50 % of the mortality caused by *A. fumigatus* infection in *G. mellonella*.

Discussion

In the last years, the incidence of fungal infections has grown dramatically leading to an increasing number of deaths worldwide (1, 2). The mortality rate is linked to a set of conditions such as the host immune system integrity, availability of an effective antifungal drug, and the occurrence of clinical resistant isolates (6, 7, 11, 28, 90). The invasive pulmonary aspergillosis (IPA) is a disease caused by the opportunistic human pathogen *A. fumigatus* and displays high levels of morbidity and mortality mainly in immunocompromised patients (1, 24). Azoles are the main drug used to control IPA but the azole-resistant *A. fumigatus* isolates have increased significantly over the last decade (35, 40–45).

Given this scenario, there is an urgent need for new antifungal therapies applied to control IPA and other fungal diseases. The development of new antifungal drugs raises challenges such as the high costs and the time required for development and licensing of new compounds. To circumvent the slowness and cost of developing new drugs, the screening of chemical libraries and repurposing of drugs that are already commercialized for other purposes is a great opportunity to discover new antifungal compounds (62, 64, 67, 71, 91–93). Here we screened the growth of *A. fumigatus* in the presence of compounds present in two drug libraries and identified 10 compounds, among them five

compounds already known as inhibitors of fungal growth including two azole-derivatives (econazole nitrate, and oxiconazole nitrate), fluvastatin, that inhibits ergosterol biosynthesis, and iodoquinol and miltefosine, drugs with an unknown mechanism of action. To our knowledge, the other five identified compounds (mesoridazine, cisapride, indinavir sulfate, enalaprilat, and vincristine sulfate) are novel as antifungal agents and have not been reported before. We investigated a possible mechanism of action for miltefosine, a chemical belonging to the alkylphosphocholine class. Miltefosine is mainly localized in the mitochondria and it has a MIC value of 4 µg/ml under *in vitro* conditions and we demonstrated that miltefosine is able to inhibit to the same extent *A. fumigatus* growth of several clinical isolates, including highly azole-resistant strains. Miltefosine was a drug initially used as an anti-neoplastic drug (94) and for treatment against trypanosomatids (95), and it is the first drug approved for oral treatment of leishmaniasis (77). However, the mechanism of action of miltefosine is not fully understood and not necessarily the same in different organisms, and the specific target of miltefosine has not been identified yet. Recent studies in trypanosomatids have suggested that miltefosine acts by: (i) altering the correct functionality of the sterol and sphingolipid metabolism (77, 78), (ii) inhibiting the phosphatidylcholine synthesis (96), and the membrane remodeling due to the phospholipase action, thus contributing to changing membrane physical properties (97), (iii) inhibiting cytochrome c oxidase (98), (iv) activating the plasma membrane Ca⁺² channel opened by the sphingolipid sphingosine and (v) destabilizing the intracellular Ca⁺² homeostasis (78). On the other hand, the resistance phenotype to miltefosine in trypanosomatids has been linked to genes belonging to lipid metabolism (99).

Concerning to its antifungal behavior, miltefosine has demonstrated to be effective against different fungal species (100–111), however, its mode of action remains to be clarified. Recent studies have suggested that miltefosine triggers its antifungal effects by destabilizing cell membranes and inducing apoptosis (102, 105, 110, 112, 113). Accordingly, Spadari and colleagues (2018) demonstrated that for *Cryptococcus spp.* miltefosine affects the plasma membrane permeability due its interaction with ergosterol and/or phospholipids increasing the production of ROS and DNA fragmentation which culminates with the fungal death by apoptosis (105). In addition, in *C. krusei*, the mode of action

of miltefosine is also supposed to be related to the binding of the drug to ergosterol in the cell membrane leading to the cell apoptosis (110).

We observed that at the MIC concentration, miltefosine displayed a fungicidal effect against *A. fumigatus*, corroborating with previous results presented for several fungal species such as *Cryptococcus* spp, *Candida* spp, and molds (101–106, 108–110, 114). Our studies showed that miltefosine could decrease 50 % *A. fumigatus* mortality in *G. mellonella* larvae. We have then decided to check if miltefosine could present any interaction with other antifungal drugs. Azoles such as posaconazole and voriconazole that act by inhibiting the ergosterol biosynthesis (115), amphotericin B that sequesters ergosterol from the cell membrane (116) and caspofungin that targets the glucan synthase Fks1 and inhibits the synthesis of β -(1,3) glucan (117) were included in our analysis and none of them showed interaction with miltefosine. Our results corroborated what was previously observed in *Aspergillus* spp where the interaction between these compounds with miltefosine was indifferent for 32 from 33 isolates (103). In contrast to our results, miltefosine has been reported to have synergy with posaconazole against *Fusarium oxysporum* and the mucormycetes (118). In addition, a recent study with *C. auris* demonstrated that for 25% of the isolates assessed there was a synergic activity between miltefosine and amphotericin B, with FICI=0.5 (110).

Sphingolipids (SL) are complex lipids composed of octadecacarbon alkaline blocks, synthesized from non-sphingolipid precursors, and representing one of the most abundant lipids in the eukaryotic cell membranes (119, 120). In fungi, SLs are involved in central cellular functions such as growth, pathogenesis, cell death, and signal transduction (121–123). The SL biosynthesis starts in the endoplasmic reticulum where the non-lipidic precursors serine and palmitoyl coenzyme A are condensed by the serine palmitoyltransferase enzyme (SPT) into 3-keto dihydrosphingosine. The SPT is specifically targeted by myriocin, a sphingolipid inhibitor (79). The interaction assay between miltefosine and myriocin showed that at high concentrations of both compounds, the FICI value was greater than 4.0 characterizing an antagonistic effect between these drugs (76). This implicates that sphingolipid metabolism may be important to the antifungal effect of miltefosine, corroborating with previous results obtained for other fungal species and trypanosomatids (77, 78, 105, 110).

We were able to identify a completely novel *A. fumigatus* transcription factor RmiA, linked to miltefosine resistance in this pathogen. This information came from a large-scale phenotypic screening of a collection of TF deletion mutants in presence of miltefosine. Although the deletion of six TFs somehow moderately impacted the growth of the mutant in presence of miltefosine, the $\Delta rmiA$ is the most sensitive mutant. RmiA is a novel and uncharacterized TF that codifies a putative Zn(II)Cys6 binuclear domain that translocates to the nucleus in presence of miltefosine and seems to be a key TF in the miltefosine response in *A. fumigatus*. Miltefosine at MIC completely abolished the $\Delta rmiA$ mutant growth and no additional phenotypes were observed under other stress conditions such as growth in presence of sub-inhibitory concentrations of posaconazole, voriconazole, caspofungin, NaCl, Calcofluor white, sorbitol, and CaCl₂. The identification of the *rmiA* gene as a putative major TF involved in *A. fumigatus* response to miltefosine provided us with an opportunity to enquire the molecular mechanisms that are regulated by this gene.

The transcriptional profiling through RNAseq assay with the wild-type strain in presence or absence of miltefosine indicated increased upregulation of genes involved in lipids/fatty acid transport and metabolism. In contrast, the RNAseq of the $\Delta rmiA$ mutant exposed to miltefosine shows exactly an opposite behavior. The lipid and fatty acid metabolism were the main category of down-regulated genes which strongly suggests that this TF participates directly or indirectly in the induction of genes involved in lipid metabolism, including genes involved in the biosynthesis of sphingolipids. The identification of RmiA represents the first genetic element described and characterized which plays a direct role in miltefosine response in fungi.

Our work provides opportunities for understanding the mechanism of action of miltefosine throughout the characterization of the genes that are differentially expressed in the $\Delta rmiA$ mutant. Further work will focus on the molecular characterization of these differentially expressed genes.

Materials and Methods

Media, strains and phenotypic characterization. The *Aspergillus* spp. used in this work are listed in the Table S1. Azole-resistant *Aspergillus fumigatus* strains were kindly provided by Katrien Lagrou and were isolated from different sources in Belgium, Switzerland, Portugal, EUA. All *Aspergillus* strains were grown in either solid minimal medium [MM: 1 % glucose (w/v), 50 mL of a 20× salt solution, trace elements, 2% agar (w/v) pH6.5] or solid complete medium [YAG: 2% glucose (w/v), 0.5% yeast extract(w/v), trace elements, 2% agar (w/v)] at 37°C. The composition of the trace elements and nitrate salts is described at Käfer, 1977. For RNAseq, ChIP-seq and lipidomics, conidia were germinated in RPMI-1640 media and transferred to liquid Vogel's Minimal Medium (VMM). For phenotypic characterization, plates containing solid MM were centrally inoculated with 10⁵ spores of each strain in presence or absence of variable concentration of miltefosine [0-8µg/mL]. After 120h of incubation at 37°C, the radial growth was measured. All plates were grown in triplicate, and averages ± standard deviations (SD) of the data are plotted. All strains used in this work are listed in the Supplementary Table S4.

Library drug screenings. Two different drug libraries were screened for antifungal activity against *A. fumigatus* CEA17 strain: The Pathogen Box (<https://www.mmv.org/mmv-open/pathogen-box>) and the National Institutes of Health (NIH) clinical collection (NCC) (<https://pubchem.ncbi.nlm.nih.gov/source/NIH%20Clinical%20Collection>). The Pathogen Box (<https://www.mmv.org/>) is a collection of 400 diverse, drug-like molecules with already described activity against different pathogens responsible for important neglected diseases such as malaria, tuberculosis, toxoplasmosis, and others. The NCC library is composed by a small molecule repository of 727 compounds which are part of screening library for the NIH Roadmap Molecular Libraries Screening Centers Network (MLSCN) corresponding to a collection of chemically diverse compounds that have been in phase I-III clinical trials (64).

For the primary screening, the drugs were diluted from 0.78-25µM in 200µL of MOPS [3-(N-morpholino) propanesulfonic acid] buffered RPMI 1640

(Life Technologies), pH 7, in 96-well plates. In each well a total of 1×10^4 conidia of *A. fumigatus* wild-type strain was inoculated. Plates were incubated for 48h at 37°C without shaking. Wells containing only medium and DMSO were used as controls. Fungal growth inhibition was determined visually as a no-growth endpoint and those compounds were selected for further studies. All experiments were done in triplicate.

Fungicidal or fungistatic activity of the selected compounds was also assessed. Briefly, a total of 1×10^4 conidia of *A. fumigatus* wild-type strain was inoculated in 96-wells plates, each well containing 200µL of MOPS buffered RPMI 1640 medium plus the lowest concentration of each compound that promoted the fungal growth inhibition in the primary screening. Plates were incubated 48h at 37°C without shaking. Following, 100 was plated in solid complete medium and incubated at 37°C for another 36h. Wells containing only medium and DMSO were used as controls. The number of viable colonies was determined by colony-forming unity (CFU) compared to the negative control (no drug), which had 100% survival. Results are expressed as means standard deviations (SD) of three independent experiments.

Minimal inhibitory concentration (MIC). The miltefosine drug used for minimal inhibitory concentration (MIC) assays was purchased from Sigma-Aldrich and solubilized in ethanol. The MIC was determined based on the M38-A2 protocol of the Clinical and Laboratory Standards Institute (125).

Briefly the assay was performed in 96-wells plates containing 200µL of MOPS buffered RPMI 1640 medium pH 7.0, supplemented with miltefosine [0-8µg/mL] and 1×10^4 conidia of *A. fumigatus*, per well. Plates were incubated at 37°C without shaking for 48h. Wells containing only medium and ethanol were used as control. The MIC value was defined as the lowest concentration of miltefosine that visually inhibited 100% of fungal growth. All experiments were done in triplicate.

Assays for checking antifungal activity of drug combinations. We checked the interaction of miltefosine with several drugs including antifungals and lipid inhibitor using a checkerboard microdilution method. The drugs concentrations ranged from 0.001 to 8.0 µg/mL for miltefosine, 0.03 - 2.0 µg/mL for

posaconazole, 0.0007 - 0.5 µg/mL for voriconazole, 4.0 - 256.0 µg/mL for caspofungin and 0.06 - 4.0 µg/mL for amphotericin B and 2.0 – 128 µg/mL for myriocin. The plates were incubated at 37°C during 48h. The MIC endpoint was 100% of growth inhibition. The interaction was quantitatively evaluated by determining the fractional inhibitory concentration index (FICI): $FICI = [MIC \text{ miltefosine in combination} / MIC \text{ miltefosine}] + [MIC \text{ clinical drug in combination} / MIC \text{ clinical drug}]$. The FICI was calculated for all possible combinations of different concentrations (126). Also, interaction curves were constructed. The interaction between these drugs was classified as synergic if $FICI \leq 0.5$, indifferent if $0.5 < FICI \leq 4.0$, and antagonistic for $FICI > 4.0$ (76).

Construction of *A. fumigatus* mutants. To generate the RmiA:3xHA mutant, a 2.9Kb fragment encompassing the rmiA ORF and the 5'UTR region, along with the 1kb 3'UTR DNA sequence, were PCR amplified from CEA17 genomic DNA (gDNA) with primer pairs P1/P2 and P4/P5 respectively. The 0.8kb 3xHA-trpC fragment was amplified from the pOB430 plasmid with primers P10/P11, the prtA gene was amplified from the plasmid pPTRI with primers P8/P9.

The RmiA:GFP strain was constructed by the amplification of a 2.9Kb fragment encompassing the rmiA ORF and the 5'UTR region, along with the 1kb 3'UTR DNA sequence, were PCR amplified from CEA17 gDNA with primer pairs P1/P3 and P4/P5 respectively. The GFP-trpC fragment was amplified from the pOB435 plasmid with primers P10/P11, the prtA gene was amplified from the plasmid pPTRI with primers P8/P9.

The $\Delta rmiA$ strain was complemented generating the $\Delta rmiA::rmiA^+$ lineage. Specifically, the fragment containing the 5'UTR plus the *rmiA* gene, along with the 1kb 3'UTR DNA sequence, were PCR amplified from CEA17 gDNA with primer pairs P1/P7 and P4/P5 respectively. In addition, these fragments were fused to the *ptrA* gene, which was previously PCR amplified from plasmid pPRTI (primers P8/P9).

All DNA cassettes (*rmiA*⁺::prtA, *rmiA*::GFP::prtA, and *rmiA*::3xHA::prtA) were constructed by *in vivo* homologous recombination by using *S. cerevisiae* (127). Briefly, the set of fragments of each of the constructions along with the plasmid pRS426 digested with BamHI/EcoRI were transformed into the *S. cerevisiae* SC9721 strain. Whole cassettes *rmiA*⁺::prtA, *rmiA*::GFP::prtA

and *rmiA::3xHA::prtA* were transformed into the $\Delta rmiA$ strain, candidates were selected by resistance to pyrithiamine and further verified via western blot, reversal of miltefosine sensitivity phenotype and/or protein functionality.

Primers used in this work are listed in the Supplementary Table S5. Additionally, the mutant strains constructed in the current work were performed into the background of the $\Delta rmiA$ strain. Positive candidates were selected in the presence of pyrithiamine, purified through three rounds of growth on plates, submitted to gDNA extraction, and confirmed by PCR.

Protein extraction and immunoblot analysis. A total of 1×10^6 conidia/mL of each strain was inoculated in 50 mL of Vogel's medium and grown at 37 °C for 16h under agitation. Mycelia were then washed with RPMI 1640 media and incubated in RPMI 1640 containing 12.5 µg/mL of miltefosine at 37°C for 0, 4 and 8h at 37°C with shaking. For protein extraction, mycelia were ground into liquid nitrogen and resuspended in 0.5mL of lysis buffer (10% (v/v) glycerol, 50 mM Tris-HCl pH 7.5, 1% (v/v) Triton X-100, 150 mM NaCl, 0.1% (w/v) SDS, 5 mM EDTA, 50 mM sodium fluoride, 5 mM sodium pyrophosphate, 50 mM - glycerophosphate, 5 mM sodium orthovanadate, 1 mM phenylmethylsulfonyl fluoride (PMSF), and 1x complete mini protease inhibitor (Roche Applied Science). Extracts were centrifuged at 16,000 g for 20 min at 4°C. The supernatants were collected, and the protein concentrations were determined using the Bradford assay (Bio-Rad). Then, 30µg of total protein extract from each sample were resolved in 10% (w/v) SDS-PAGE and transferred to a nitrocellulose membrane for a Western blot assay. Monoclonal anti-HA antibody (Sigma-aldrich) was used to confirm the *RmiA::3xHA* expression. In addition, anti- α -actin antibody was used to normalize the protein loading. The primary antibodies were detected using a horseradish peroxidase (HRP)-conjugated secondary antibody raised in mouse (Sigma-Aldrich). Chemiluminescent detection was achieved using an ECL Prime Western blotting detection kit (GE Healthcare). To detect these signals on blotted membranes, the ECL Prime Western blotting detection system (GE Healthcare, Little Chalfont, UK) and LAS1000 (Fujifilm, Tokyo, Japan) were used.

Real-time PCR analysis. Total cellular RNA was extracted using TRIzol reagent (Invitrogen, Life Technologies, Camarillo, CA, USA). Further, RNA was submitted to DNA digestion with RQ1 RNase-free DNase (Promega, Fitchburg, WI, USA) according to the manufacturer's instructions. The cDNA synthesis was performed by the ImProm-II™ Reverse Transcription System (Promega) and oligo(dT). The real-time PCR was performed using the ABI 7500 Fast Real-Time PCR System (Applied Biosystems, Foster City, CA, USA) and the SYBR Green PCR Master Mix kit (Applied Biosystems), according to manufacturer's instructions. Analysis were carried-out using three independent biological replicates. The mRNA quantity relative fold change data was calculated using standard curves (128) and normalized by the expression levels of the housekeeping β -tubulin gene. Primer sequences used in this study are listed in Supplementary Table S5.

RNA purification and preparation for RNA-Seq. A total of 10^6 spores/ml of *A. fumigatus* WT and $\Delta rmiA$ were inoculated in 50 ml of Vogel's medium and grown at 37 °C for 16h under agitation. The suspensions were centrifuged and washed with PBS. Mycelia was suspended in VMM media containing glucose supplemented with 3 μ g/mL of miltefosine, or in the absence of any drug, and incubated at 37 °C for additional 30 min. Total RNA was extracted by Trizol method. Subsequently, 10 μ g of total RNAs were subjected to RNA purification using DNase I (New England Biolabs Inc.) and the quality was checked on 2% agarose gel and verified using the Agilent Bioanalyser 2100 (Agilent technologies). RNAs selected for further analysis had a minimum RNA Integrity Number (RIN) value of 8.0. One μ g of purified RNAs were used for library preparation using Illumina NEBNext® Ultra™ Directional RNA Library Prep Kit according to manufacturer's protocol and sequenced using the Illumina HiSeq2500 platform at the Genomics and Single Cells Analysis Core facility at the University of Macau. The expression levels were calculated in RPKM and for the differential expression analysis a $\log_2\text{FoldChange}$ of $-1 \leq \log_2\text{FC} \leq 1$ was applied to capture minimum 2 times perturbation on the expression levels, with the $P < 0.005$ and false-discovery rate (FDR) lower than 0.05.

Chromatin preparation. A similar experimental design used for the RNA seq was used for the ChIP seq experiments. After growth, the cultures were added

with 1% formaldehyde for 20 minutes with gentle shaking at room temperature, then a final concentration of 0.5M glycine was added to further incubation for 10 minutes. The mycelia were collected by filtering and washed with cold water. The crosslinked mycelia were frozen in liquid nitrogen and frozen dried for 2 hours before lysis. The cell lysis was processed by 6 times beating for 3 minutes with ~100 μ l volume of silica beads using Bullet Blender (Next Advance) with 3 minutes of cooling in between each cycle. Chromatins were extracted as described (129) and sonicated using the Qsonica Q800R at 100% amplitude with 10 seconds ON and 15 seconds OFF cycles for a total sonication time of 30 minutes. Chromatin concentration and size (100-500bp) were checked on 2% agarose gel, and the prepared chromatins were stored at -80 °C until use.

Chromatin Immuno-precipitation and sequencing library preparation.

Immuno-precipitation was carried out using anti-HA antibody as described previously (130). Immuno-precipitated materials were purified using QIAGEN PCR clean-up kit, and multiplexed sequencing libraries were prepared as described (130) using NEBNext® Ultra™ II DNA Library Prep Kit for Illumina according to manufacturer's protocol. Libraries were checked and quantified using DNA High Sensitivity Bioanalyser assay, mixed in equal molar ratio and sequenced using the Illumina HiSeq2500 platform at the Genomics and Single Cells Analysis Core facility at the University of Macau.

Data mapping and bioinformatics analysis. Raw sequencing reads of ChIPseq experiments were quality-checked using FastQC (<http://www.bioinformatics.babraham.ac.uk/projects/fastqc/>) and aligned to Af293 reference genome (genome version s03-m05-r06) using Bowtie2 (version: 2.2.9) (131). For peaks calling, MACS2 was applied. In order to determine the presence of conserved RmiA DNA binding motifs we carried out a MEME (Multiple EM for Motif Elicitation)-ChIP analysis to search the 500 bp region surrounding the peaks identified in our ChIP-seq data (<http://meme-suite.org>).

Lipid analysis. A total of 10^6 spores/ml of *A. fumigatus* WT and Δ Afub_027770 were inoculated in 50 ml of Vogel's medium and grown at 37 °C for 16h under agitation. The suspensions were centrifuged and washed with PBS. Mycelia was

suspended in VMM media containing glucose supplemented with 3 $\mu\text{g/mL}$ of miltefosine, or in the absence of any drug, and incubated at 37 °C for additional 4h. Prior to cell lysis, C17-sphingolipids were added to the samples (132, 133). Mandala extraction was carried out as described previously (134), with a few modifications. To facilitate the disruption of mycelia, the samples were vortexed and sonicated for 2 min in the presence of 0.2 g of glass beads. Then, the samples were submitted to Bligh and Dyer Extraction (135). A quarter of each sample obtained from the Bligh and Dyer Extraction was reserved for inorganic phosphate (Pi) determination, so the relative sphingolipid signal was normalized by the Pi abundance. The organic phase was transferred to a new tube and submitted to alkaline hydrolysis of phospholipids (136). Finally, the organic phase was dried and used for mass spectrometry analysis (133).

Statistical analysis. Grouped column plots with standard deviation error bars were used for representations of data. For comparisons with data from wild-type or control conditions, we performed one-tailed, paired *t* tests or one-way analysis of variance (ANOVA). All statistical analysis and graphics building were performed by using GraphPad Prism 5.00 (GraphPad Software).

Fluorescence microscopy. A total of 10^5 spores of each strain was inoculated on coverslips in 4 ml of MM medium for 16 h at 30°C. After, coverslips with adherent germlings were left untreated or miltefosine for different periods of time, as indicated. Staining procedures included: (i) 5 min of incubation in a solution with Propidium Iodide (PI [0.05mg/ml], Sigma Aldrich); (ii) 5min of incubation in a solution with MitoTracker Deep Red™ FM dye ([250nM], Invitrogen); (iii) 10min of incubation in a solution containing Hoechst 33342 dye (20 $\mu\text{g/mL}$, Molecular Probes, Eugene, OR, USA). Further, the coverslips were rinsed with phosphate-buffered saline (PBS; 140 mM NaCl, 2 mM KCl, 10 mM NaHPO₄, 1.8 mM KH₂PO₄, pH 7.4). Slides were visualized on the Observer Z1 fluorescence microscope using a 100x objective oil immersion lens. Differential interference contrast images (DIC) and fluorescent images were captured with AxioCam camera (Carl Zeiss) and processed using AxioVision software (version 4.8). In each experiment, at least 50 gemlings were counted. For GFP the wavelength excitation was 450 to 490 nm and emission wavelength of 500 to 550 nm. For

MitoTracker Deep RedTM FM the wavelength abs/em was about 644/665 nm. For Hoechst [4,6-diamidino-2-phenylindole] staining, the excitation wavelength was 365 nm and emission wavelength 420-470 nm. For PI the wavelength excitation was 572/25 nm and emission wavelength was 629/62 nm.

Virulence analysis in *Galleria mellonella* model. The *Galleria mellonella* larvae were obtained by breeding adult larvae (137) weighting 275-330 mg. The larvae were kept in starvation in Petri dishes at 37° in the dark for 24 hours prior to infection. The larvae used for the experiment were in the sixth stage of development. For infection, fresh spores from each strain (mutants and wild-type) were used. The spores of each strain were counted using a hemocytometer. The stock concentration of spore suspensions used for infection was 2×10^8 conidia/ml, and from this stock 5ul were used for larval infection (1×10^6 conidia/larva). The control group was composed of larvae inoculated with 5 µl of PBS to observe any possible death caused by physical trauma. The inoculum was performed using a Hamilton syringe (7000.5KH) and the conidia were inoculated into the lower left proleg of the larvae. After 30 minutes of the larvae being infected, treatment with miltefosine (M5571 Sigma-Aldrich) was carried out. The drug was rehydrated in distilled water as recommended by the manufacturer (102). The concentrations used for the treatments were 40, 60 and 80 mg/kg of the larvae and each larva was weighted individually, and the volume was adjusted to the pre-established concentrations. As a control for the treatments, we made three groups of larvae in which concentrations of 40, 60 and 80mg / kg were injected. The treatments were also injected into the lower right proleg of the larvae. After infection, the larvae were kept at 37 ° in Petri dishes in the dark and scored daily. Larvae were considered dead due to lack of movement in response to touch. The viability of the inoculum administered was determined by plating a serial dilution of the conidia in YAG medium. The statistical significance of the comparative survival values was calculated using the log rank analysis of Mantel-Cox and Gehan-Brestow-Wilcoxon by using the statistical analysis package Prism (138).

Data availability statement. The datasets generated for this study are available on request to the corresponding author.

Funding information

This study was supported by the Brazilian funding agencies Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP, 2016/12948-7) and Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq). This work was also supported by the National Institutes of Health grants AI136934 and AI125770 to MDP, and a Merit Grant I01BX002924 from the Veterans Affairs Program to MDP. K.H.W. was supported by the Research Services and Knowledge Transfer Office of the University of Macau (Grant number: MYRG2019-00099-FHS).

Conflict of Interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. Dr. Maurizio Del Poeta, M.D. is a Co-Founder and Chief Scientific Officer (CSO) of MicroRid Technologies Inc.; Dra Thaila Fernanda dos Reis is a Co-Founder of MicroControl Innovation. MLR is currently on leave from the position of associate professor at the Microbiology Institute of the Federal University of Rio de Janeiro, Brazil.

References

1. Brown GD, Denning DW, Gow NAR, Levitz SM, Netea MG, White TC. 2012. Hidden killers: Human fungal infections. *Sci Transl Med* 4.
2. Brown GD, Denning DW, Levitz SM. 2012. Tackling human fungal infections. *Science* (80-) 336:647.
3. Roemer T, Krysan DJ. 2014. Antifungal Drug Development: Challenges, Unmet Clinical Needs, and New Approaches. *Cold Spring Harb Perspect Med* 4:a019703.
4. Calderone R, Gay-Andrieu F, Li D, Sun N, Groutas W, Weerawarna P, Prasad S, Alex D. 2014. Antifungal drug discovery: The process and

outcomes. *Future Microbiol* 9:791–805.

5. Denning DW, Bromley MJ. 2015. How to bolster the antifungal pipeline. *Science* (80-) 347:1414–1416.

6. Mayer FL, Wilson D, Hube B. 2013. *Candida albicans* pathogenicity mechanisms. *Virulence* 4:119–128.

7. Abad A, Victoria Fernández-Molina J, Bikandi J, Ramírez A, Margareto J, Sendino J, Luis Hernando F, Pontón J, Garaizar J, Rementeria A. 2010. ¿Qué hace que *Aspergillus fumigatus* sea un patógeno de éxito? Genes y moléculas involucrados en la aspergilosis invasora. *Rev Iberoam Micol* 27:155–182.

8. Lee IR, Yang L, Sebetso G, Allen R, Doan THN, Blundell R, Lui EYL, Morrow CA, Fraser JA. 2013. Characterization of the Complete Uric Acid Degradation Pathway in the Fungal Pathogen *Cryptococcus neoformans*. *PLoS One* 8:1–13.

9. Rüping MJGT, Vehreschild JJ, Cornely OA. 2008. Patients at High Risk of Invasive Fungal Infections. *Drugs* 68:1941–1962.

10. Guinea J, Torres-Narbona M, Gijón P, Muñoz P, Pozo F, Peláez T, de Miguel J, Bouza E. 2010. Pulmonary aspergillosis in patients with chronic obstructive pulmonary disease: Incidence, risk factors, and outcome. *Clin Microbiol Infect* 16:870–877.

11. Gonçalves SS, Souza ACR, Chowdhary A, Meis JF, Colombo AL. 2016. Epidemiology and molecular mechanisms of antifungal resistance in *Candida* and *Aspergillus*. *Mycoses* 59:198–219.

12. Rudramurthy SM, Paul RA, Chakrabarti A, Mouton JW, Meis JF. 2019. Invasive aspergillosis by *aspergillus flavus*: Epidemiology, diagnosis, antifungal resistance, and management. *J Fungi* 5:1–23.

13. Patterson TF, Thompson GR, Denning DW, Fishman JA, Hadley S, Herbrecht R, Kontoyiannis DP, Marr KA, Morrison VA, Nguyen MH, Segal BH, Steinbach WJ, Stevens DA, Walsh TJ, Wingard JR, Young JAH, Bennett JE. 2016. Executive summary: Practice guidelines for the

- 1015 diagnosis and management of aspergillosis: 2016 update by the
1016 infectious diseases society of America. Clin Infect Dis 63:433–442.
- 1017 14. Perlin DS, Rautemaa-Richardson R, Alastruey-Izquierdo A. 2017. The
1018 global problem of antifungal resistance: prevalence, mechanisms, and
1019 management. Lancet Infect Dis 17:e383–e392.
- 1020 15. Alastruey-Izquierdo A, Cadranet J, Flick H, Godet C, Hennequin C,
1021 Hoenigl M, Kosmidis C, Lange C, Munteanu O, Page I, Salzer HJF. 2018.
1022 Treatment of Chronic Pulmonary Aspergillosis: Current Standards and
1023 Future Perspectives. Respiration 96:159–170.
- 1024 16. Denning DW, Cadranet J, Beigelman-Aubry C, Ader F, Chakrabarti A,
1025 Blot S, Ullmann AJ, Dimopoulos G, Lange C. 2016. Chronic pulmonary
1026 aspergillosis: Rationale and clinical guidelines for diagnosis and
1027 management. Eur Respir J 47:45–68.
- 1028 17. Latgé, Jean-Paul ; Chamilos G. 2020. Aspergillus fumigatus and
1029 Aspergillosis in 2019. Clin Microbiol Rev 33:1–75.
- 1030 18. Tekaia F, Latgé JP. 2005. Aspergillus fumigatus: Saprophyte or
1031 pathogen? Curr Opin Microbiol 8:385–392.
- 1032 19. Agarwal R, Chakrabarti A, Shah A, Gupta D, Meis JF, Guleria R, Moss R,
1033 Denning DW. 2013. Allergic bronchopulmonary aspergillosis: Review of
1034 literature and proposal of new diagnostic and classification criteria. Clin
1035 Exp Allergy 43:850–873.
- 1036 20. Van De Veerdonk FL, Gresnigt MS, Romani L, Netea MG, Latgé JP.
1037 2017. Aspergillus fumigatus morphology and dynamic host interactions.
1038 Nat Rev Microbiol 15:661–674.
- 1039 21. Gergen PJ, Arbes SJ, Calatroni A, Mitchell HE, Zeldin DC. 2009. Total
1040 IgE levels and asthma prevalence in the US population: Results from the
1041 National Health and Nutrition Examination Survey 2005-2006. J Allergy
1042 Clin Immunol 124:447–453.
- 1043 22. Vacher G, Niculita-Hirzel H, Roger T. 2015. Immune responses to
1044 airborne fungi and non-invasive airway diseases. Semin Immunopathol

- 1045 37:83–96.
- 1046 23. Kosmidis C, Denning DW. 2015. The clinical spectrum of pulmonary
1047 aspergillosis. *Thorax* 70:270–277.
- 1048 24. Azie N, Neofytos D, Pfaller M, Meier-Kriesche HU, Quan SP, Horn D.
1049 2012. The PATH (Prospective Antifungal Therapy) Alliance® registry and
1050 invasive fungal infections: Update 2012. *Diagn Microbiol Infect Dis*
1051 73:293–300.
- 1052 25. Almyroudis NG, Holland SM, Segal BH. 2005. Invasive aspergillosis in
1053 primary immunodeficiencies. *Med Mycol* 43:247–259.
- 1054 26. Nett JE, Andes DR. 2016. Antifungal Agents: Spectrum of Activity,
1055 Pharmacology, and Clinical Indications. *Infect Dis Clin North Am* 30:51–
1056 83.
- 1057 27. Holt SL, Drew RH. 2011. Echinocandins: Addressing outstanding
1058 questions surrounding treatment of invasive fungal infections. *Am J Heal*
1059 *Pharm* 68:1207–1220.
- 1060 28. Perfect JR. 2017. The antifungal pipeline: A reality check. *Nat Rev Drug*
1061 *Discov* 16:603–616.
- 1062 29. Allen D, Wilson D, Drew R, Perfect J. 2015. Azole antifungals: 35 years of
1063 invasive fungal infection management. *Expert Rev Anti Infect Ther*
1064 13:787–798.
- 1065 30. Denning DW, O'Driscoll BR, Hogaboam CM, Bowyer P, Niven RM. 2006.
1066 The link between fungi and severe asthma: A summary of the evidence.
1067 *Eur Respir J* 27:615–626.
- 1068 31. Fontaine T, Delangle A, Simenel C, Coddeville B, van Vliet SJ, van Kooyk
1069 Y, Bozza S, Moretti S, Schwarz F, Trichot C, Aebi M, Delepierre M, Elbim
1070 C, Romani L, Latgé JP. 2011. Galactosaminogalactan, a new
1071 immunosuppressive polysaccharide of *Aspergillus fumigatus*. *PLoS*
1072 *Pathog* 7.
- 1073 32. Hanadate T, Wakasugi M, Sogabe K, Kobayashi T, Horita H, Kawamura I,
1074 Hori Y, Matsui K, Hoshino Y, Sou M. 2011. Evaluation of the safety and

- efficacy of micafungin in Japanese patients with deep mycosis: A post-marketing survey report. *J Infect Chemother* 17:622–632.
33. Walsh, Thomas J Elias J. Anaissie 2, David W. Denning 13, Raoul Herbrecht, 14 Dimitrios P. Kontoyiannis 3, Kieren A. Marr, 5 Vicki A. Morrison, 6 7, Brahm H Segal 8, William J. Steinbach 9, David A. Stevens, 10 11, Jo-Anne van Burik, 7 John R. Wingard 12, Patterson4 and TF, Tang XD, Li GH. 2008. Treatment of aspergillosis: Clinical practice guidelines of Infectious Diseases Society of America. *Chinese J Infect Chemother* 8:161–166.
34. Maertens J, Raad I, Petrikos G, Boogaerts M, Selleslag D, Petersen FB, Sable CA, Kartsonis NA, Ngai A, Taylor A, Patterson TF, Denning DW, Walsh TJ. 2004. Efficacy and Safety of Caspofungin for Treatment of Invasive Aspergillosis in Patients Refractory to or Intolerant of Conventional Antifungal Therapy. *Clin Infect Dis* 39:1563–1571.
35. Verweij PE, Lestrade PPA, Melchers WJG, Meis JF. 2016. Azole resistance surveillance in *Aspergillus fumigatus*: Beneficial or biased? *J Antimicrob Chemother* 71:2079–2082.
36. Maertens JA, Raad II, Marr KA, Patterson TF, Kontoyiannis DP, Cornely OA, Bow EJ, Rahav G, Neofytos D, Aoun M, Baddley JW, Giladi M, Heinz WJ, Herbrecht R, Hope W, Karthaus M, Lee DG, Lortholary O, Morrison VA, Oren I, Selleslag D, Shoham S, Thompson GR, Lee M, Maher RM, Schmitt-Hoffmann AH, Zeiher B, Ullmann AJ. 2016. Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by *Aspergillus* and other filamentous fungi (SECURE): A phase 3, randomised-controlled, non-inferiority trial. *Lancet* 387:760–769.
37. Miceli MH, Kauffman CA. 2015. Isavuconazole: A New Broad-Spectrum Triazole Antifungal Agent. *Clin Infect Dis* 61:1558–1565.
38. Tissot F, Agrawal S, Pagano L, Petrikos G, Groll AH, Skiada A, Lass-Flörl C, Calandra T, Viscoli C, Herbrecht R. 2017. ECIL-6 guidelines for the treatment of invasive candidiasis, aspergillosis and mucormycosis in leukemia and hematopoietic stem cell transplant patients. *Haematologica*

102:433–444.

39. Ullmann AJ, Aguado JM, Arikan-Akdagli S, Denning DW, Groll AH, Lagrou K, Lass-Flörl C, Lewis RE, Munoz P, Verweij PE, Warris A, Ader F, Akova M, Arendrup MC, Barnes RA, Beigelman-Aubry C, Blot S, Bouza E, Brüggemann RJM, Buchheidt D, Cadranel J, Castagnola E, Chakrabarti A, Cuenca-Estrella M, Dimopoulos G, Fortun J, Gangneux JP, Garbino J, Heinz WJ, Herbrecht R, Heussel CP, Kibbler CC, Klimko N, Kullberg BJ, Lange C, Lehrnbecher T, Löffler J, Lortholary O, Maertens J, Marchetti O, Meis JF, Pagano L, Ribaud P, Richardson M, Roilides E, Ruhnke M, Sanguinetti M, Sheppard DC, Sinkó J, Skiada A, Vehreschild MJGT, Viscoli C, Cornely OA. 2018. Diagnosis and management of *Aspergillus* diseases: executive summary of the 2017 ESCMID-ECMM-ERS guideline. *Clin Microbiol Infect* 24:e1–e38.
40. Garcia-Rubio R, Cuenca-Estrella M, Mellado E. 2017. Triazole Resistance in *Aspergillus* Species: An Emerging Problem. *Drugs* 77:599–613.
41. Sharpe AR, Lagrou K, Meis JF, Chowdhary A, Lockhart SR, Verweij PE. 2018. Triazole resistance surveillance in *Aspergillus fumigatus*. *Med Mycol* 56:S83–S92.
42. Arikan-Akdagli S, Ghannoum M, Meis JF. 2018. Antifungal resistance: specific focus on multidrug resistance in *Candida auris* and secondary azole resistance in *Aspergillus fumigatus*. *J Fungi* 4:1–13.
43. Chen P, Liu J, Zeng M, Sang H. 2020. Exploring the molecular mechanism of azole resistance in *Aspergillus fumigatus*. *J Mycol Med* 30:100915.
44. Wiederhold NP, Verweij PE. 2020. *Aspergillus fumigatus* and pan-azole resistance: who should be concerned? *Curr Opin Infect Dis* 33:290–297.
45. Wiederhold NP. 2017. Antifungal resistance: current trends and future strategies to combat. *Infect Drug Resist* 10:249–259.
46. Snelders E, Van Der Lee HAL, Kuijpers J, Rijs AJMM, Varga J, Samson RA, Mellado E, Donders ART, Melchers WJG, Verweij PE. 2008.

- Emergence of azole resistance in *Aspergillus fumigatus* and spread of a single resistance mechanism. *PLoS Med* 5:1629–1637.
47. Camps SMT, Rijs AJMM, Klaassen CHW, Meis JF, O’Gorman CM, Dyer PS, Melchers WJG, Verweij PE. 2012. Molecular epidemiology of *Aspergillus fumigatus* isolates harboring the TR34/L98H azole resistance mechanism. *J Clin Microbiol* 50:2674–2680.
48. Meneau I, Sanglard D. 2005. Azole and fungicide resistance in clinical and environmental *Aspergillus fumigatus* isolates. *Med Mycol* 43:307–311.
49. Toyotome T. 2019. Resistance in the environmental pathogenic fungus *Aspergillus fumigatus*. *Med Mycol J* 60:61–63.
50. Blosser SJ, Cramer RA. 2012. SREBP-Dependent Triazole Susceptibility in *Aspergillus fumigatus* is Mediated through Direct Transcriptional Regulation of *erg11A* (*cyp51A*). *Antimicrob Agents Chemother* 56:248–257.
51. Fraczek MG, Bromley M, Buied A, Moore CB, Rajendran R, Rautemaa R, Ramage G, Denning DW, Bowyer P. 2013. The *cdr1B* efflux transporter is associated with non- *cyp51a* -mediated itraconazole resistance in *Aspergillus fumigatus*. *J Antimicrob Chemother* 68:1486–1496.
52. Buied A, Moore CB, Denning DW, Bowyer P. 2013. High-level expression of *cyp51B* in azole-resistant clinical *Aspergillus fumigatus* isolates. *J Antimicrob Chemother* 68:512–514.
53. Rajendran R, Mowat E, Mcculloch E, Lappin DF, Jones B, Lang S, Majithiya JB, Warn P, Williams C, Ramage G. 2011. Azole Resistance of *Aspergillus fumigatus* Biofilms Is Partly Associated with Efflux Pump Activity. *Antimicrob Agents Chemother* 55:2092–2097.
54. Hagiwara D, Watanabe A, Kamei K, Goldman GH. 2016. Epidemiological and genomic landscape of azole resistance mechanisms in *Aspergillus* fungi. *Front Microbiol* 7:1–14.

55. Hagiwara D, Watanabe A, Kamei K. 2016. Sensitisation of an Azole-Resistant *Aspergillus fumigatus* Strain containing the Cyp51A-Related Mutation by Deleting the *SrbA* Gene. *Sci Rep* 6:1–8.
56. Gonzalez-Lara MF, Roman-Montes CM, Diaz-Lomeli P, Rangel-Cordero A, Valenzuela MO, Ponce-De-Leon A, Sifuentes-Osornio J, Ostrosky-Zeichner L, Martinez-Gamboa A. 2019. Azole resistance and *cyp51A* mutation screening in *Aspergillus fumigatus* in Mexico. *J Antimicrob Chemother* 74:2047–2050.
57. Lestrade PPA, Meis JF, Melchers WJG, Verweij PE. 2019. Triazole resistance in *Aspergillus fumigatus*: recent insights and challenges for patient management. *Clin Microbiol Infect* 25:799–806.
58. Lass-Flörl C, Kofler G, Kropshofer G, Hermans J, Kreczy A, Dierich MP, Niederwieser D. 1998. In-vitro testing of susceptibility to amphotericin B is a reliable predictor of clinical outcome in invasive aspergillosis. *J Antimicrob Chemother* 42:497–502.
59. Hadrich I, Makni F, Neji S, Cheikhrouhou F, Bellaaj H, Elloumi M, Ayadi A, Ranque S. 2012. Amphotericin B in vitro resistance is associated with fatal *Aspergillus flavus* infection. *Med Mycol* 87:829–834.
60. Reichert-Lima F, Lyra L, Pontes L, Moretti ML, Pham CD, Lockhart SR, Schreiber AZ. 2018. Surveillance for azoles resistance in *Aspergillus* spp. highlights a high number of amphotericin B-resistant isolates. *Mycoses* 61:360–365.
61. Vahedi Shahandashti R, Lass-Flörl C. 2019. Antifungal resistance in *Aspergillus terreus*: A current scenario. *Fungal Genet Biol* 131:103247.
62. Oliver JD, Sibley GEM, Beckmann N, Dobb KS, Slater MJ, McEntee L, du Pré S, Livermore J, Bromley MJ, Wiederhold NP, Hope WW, Kennedy AJ, Law D, Birch M. 2016. F901318 represents a novel class of antifungal drug that inhibits dihydroorotate dehydrogenase. *Proc Natl Acad Sci* 113:12809–12814.
63. Moreno-Martinez E, Vallieres C, Holland SL, Avery S V. 2015. Novel, Synergistic Antifungal Combinations that Target Translation Fidelity. *Sci*

- 1198 Rep 5:1–11.
- 1199 64. Joffe LS, Schneider R, Lopes W, Azevedo R, Staats CC, Kmetzsch L,
1200 Schrank A, Poeta M Del, Vainstein MH, Rodrigues ML. 2017. The anti-
1201 helminthic compound mebendazole has multiple antifungal effects against
1202 *Cryptococcus neoformans*. *Front Microbiol* 8:1–14.
- 1203 65. Nicola Nosengo. 2016. Can you teach old drugs new tricks? *Nature*
1204 534:314–316.
- 1205 66. Kaul G, Shukla M, Dasgupta A, Chopra S. 2019. Update on drug-
1206 repurposing: Is it useful for tackling antimicrobial resistance? *Future*
1207 *Microbiol* 14:829–831.
- 1208 67. Rhein J, Morawski BM, Hullsiek KH, Nabeta HW, Kiggundu R, Tugume L,
1209 Musubire A, Akampurira A, Smith KD, Alhadab A, Williams DA, Abassi M,
1210 Bahr NC, Velamakanni SS, Fisher J, Nielsen K, Meya DB, Boulware DR,
1211 Ndyetukira JF, Ahimbisibwe C, Kugonza F, Sadiq A, Kandole TK, Luggya
1212 T, Kaboggoza J, Laker E, Butler EK, Dyal J, Neborak JM, King AM, Fujita
1213 AW, Yueh N, Namudde A, Halupnick R, Jawed B, Vedula P, Peterson M,
1214 Bohjanen PR, Kambugu A. 2016. Efficacy of adjunctive sertraline for the
1215 treatment of HIV-associated cryptococcal meningitis: An open-label dose-
1216 ranging study. *Lancet Infect Dis* 16:809–818.
- 1217 68. Duffy S, Sykes ML, Jones AJ, Shelper TB, Simpson M, Lang R, Poulsen
1218 SA, Sleebs BE, Avery VM. 2017. Screening the medicines for malaria
1219 venture pathogen box across multiple pathogens reclassifies starting
1220 points for open-source drug discovery. *Antimicrob Agents Chemother* 61.
- 1221 69. Hennessey KM, Rogiers IC, Shih HW, Hulverson MA, Choi R, McCloskey
1222 MC, Whitman GR, Barrett LK, Merritt EA, Paredes AR, Ojo KK. 2018.
1223 Screening of the Pathogen Box for inhibitors with dual efficacy against
1224 *Giardia lamblia* and *Cryptosporidium parvum*. *PLoS Negl Trop Dis* 12:1–
1225 16.
- 1226 70. Spalenka J, Sandie Escotte-Binet, Ali Bakiri, Jane Hubert, Jean-Hugues
1227 Renault, Frédéric Velard, Simon Duchateau, Dominique Aubert, Antoine
1228 Huguenin IV. 2018. crossm Discovery of New Inhibitors of *Toxoplasma*

gondii via the 62:1–10.

71. Wall G, Herrera N, Lopez-Ribot JL. 2019. Repositionable compounds with antifungal activity against multidrug resistant candida auris identified in the medicines for malaria venture's pathogen box. *J Fungi* 5.
72. Dorlo TPC, Balasegaram M, Beijnen JH, de vries PJ. 2012. Miltefosine: A review of its pharmacology and therapeutic efficacy in the treatment of leishmaniasis. *J Antimicrob Chemother* 67:2576–2597.
73. Sundar S. 2009. An Update on Pharmacotherapy for Leishmaniasis Shyam 16:186–189.
74. Simm C, May RC. 2019. Zinc and Iron Homeostasis : Target-Based Drug Screening as New Route for Antifungal Drug Development. *Front Cell Infect Microbiol* 9:1–12.
75. Santos JRA, Gouveia LF, Taylor ELS, Resende-Stoianoff MA, Pianetti GA, César IC, Santos DA. 2012. Dynamic Interaction between Fluconazole and Amphotericin B against *Cryptococcus gattii*. *Antimicrob Agents Chemother* 56:2553–2558.
76. Odds FC. 2003. Synergy , antagonism , and what the chequerboard puts between them. *J Antimicrob Chemother* 52:273144.
77. Armitage EG, Alqaisi AQL, Godzien J, Peña I, Mbekeani AJ, Alonso-Herranz V, López-González Á, Martín J, Gabarro R, Denny PW, Barrett MP, Barbas C. 2018. Complex interplay between sphingolipid and sterol metabolism revealed by perturbations to the leishmania metabolome caused by miltefosine. *Antimicrob Agents Chemother* 62:1–12.
78. Pinto-Martinez AK, Rodriguez-Durán J, Serrano-Martin X, Hernandez-Rodriguez V, Benaim G. 2018. Mechanism of action of miltefosine on *Leishmania donovani* involves the impairment of acidocalcisome function and the activation of the sphingosine-dependent plasma membrane Ca²⁺ channel. *Antimicrob Agents Chemother* 62:1–10.
79. Miyake Y, Kozutsumi Y, Nakamura S, Fujita T, Kawasaki T. 1995. Serine palmitoyltransferase is 735 the primary target of a sphingosine-like

- 1259 immunosuppressant, ISP-1/myriocin. *Biochem Biophys Res Commun*
1260 211.
- 1261 80. Furukawa T, van Rhijn N, Fraczek M, Gsaller F, Davies E, Carr P, Gago
1262 S, Fortune-Grant R, Rahman S, Gilsenan JM, Houlder E, Kowalski CH,
1263 Raj S, Paul S, Cook P, Parker JE, Kelly S, Cramer RA, Latgé JP, Moye-
1264 Rowley S, Bignell E, Bowyer P, Bromley MJ. 2020. The negative cofactor
1265 2 complex is a key regulator of drug resistance in *Aspergillus fumigatus*.
1266 *Nat Commun* 11.
- 1267 81. Ukil L, Varadaraj A, Govindaraghavan M, Liu HL, Osmani SA. 2008. Copy
1268 number suppressors of the *Aspergillus nidulans* nimA1 mitotic kinase
1269 display distinctive and highly dynamic cell cycle-regulated locations.
1270 *Eukaryot Cell* 7:2087–2099.
- 1271 82. Bertuzzi M, Schrettl M, Alcazar-Fuoli L, Cairns TC, Muñoz A, Walker LA,
1272 Herbst S, Safari M, Cheverton AM, Chen D, Liu H, Saijo S, Fedorova ND,
1273 Armstrong-James D, Munro CA, Read ND, Filler SG, Espeso EA,
1274 Nierman WC, Haas H, Bignell EM. 2014. The pH-Responsive PacC
1275 Transcription Factor of *Aspergillus fumigatus* Governs Epithelial Entry and
1276 Tissue Invasion during Pulmonary Aspergillosis. *PLoS Pathog* 10.
- 1277 83. Dinamarco TM, Almeida RS, de Castro PA, Brown NA, dos Reis TF,
1278 Ramalho LN, Savoldi M, Goldman MHS, Goldman GH. 2012. Molecular
1279 characterization of the putative transcription factor SebA involved in
1280 virulence in *Aspergillus fumigatus*. *Eukaryot Cell* 11.
- 1281 84. Neubauer M, Zhu Z, Penka M, Helmschrott C, Wagener N, Wagener J.
1282 2015. Mitochondrial dynamics in the pathogenic mold *Aspergillus*
1283 *fumigatus*: Therapeutic and evolutionary implications. *Mol Microbiol*
1284 98:930–945.
- 1285 85. Ruf D, Brantl V, Wagener J. 2018. Mitochondrial fragmentation in
1286 *Aspergillus fumigatus* as early marker of granulocyte killing activity. *Front*
1287 *Cell Infect Microbiol* 8.
- 1288 86. Hornillos V, Carrillo E, Rivas L, Amat-Guerri F, Acuña AU. 2008.
1289 Synthesis of BODIPY-labeled alkylphosphocholines with leishmanicidal

- 1290 activity, as fluorescent analogues of miltefosine. *Bioorganic Med Chem*
1291 *Lett* 18:6336–6339.
- 1292 87. Nakahara K, Ohkuni A, Kitamura T, Abe K, Naganuma T, Ohno Y, Zoeller
1293 RA, Kihara A. 2012. The Sjögren-Larsson Syndrome Gene Encodes a
1294 Hexadecenal Dehydrogenase of the Sphingosine 1-Phosphate
1295 Degradation Pathway. *Mol Cell* 46:461–471.
- 1296 88. Bastos RW, Rossato L, Valero C, Lagrou K, Colombo AL, Goldman GH.
1297 2019. Potential of Gallium as an Antifungal Agent. *Front Cell Infect*
1298 *Microbiol* 9:1–11.
- 1299 89. Riat A, Plojoux J, Gindro K, Schrenzel J. 2018. Azole Resistance of
1300 Environmental and Clinical *Aspergillus*. *Antimicrob Agents Chemother*
1301 62:1–7.
- 1302 90. Colombo AL, de Almeida Júnior JN, Slavin MA, Chen SCA, Sorrell TC.
1303 2017. *Candida* and invasive mould diseases in non-neutropenic critically
1304 ill patients and patients with haematological cancer. *Lancet Infect Dis*
1305 17:e344–e356.
- 1306 91. Mayer FL, Kronstad JW. 2017. Discovery of a Novel Antifungal Agent in
1307 the Pathogen Box. *mSphere* 2:1–12.
- 1308 92. Scorneaux B, Angulo D, Borroto-esoda K. 2017. SCY-078 Is Fungicidal
1309 against *Candida* Species in time-kill studies. *Antimicrob Agents*
1310 *Chemother* 61:1–10.
- 1311 93. Vallières C, Avery S. 2017. The Candidate Antimalarial Drug MMV665909
1312 Causes Oxygen-Dependent mRNA Mistranslation and Synergizes with
1313 Quinoline-Derived Antimalarials. *Antimicrob Agents Chemother* 61:1–11.
- 1314 94. Eibl H, Ungert C. 1990. Hexadecylphosphocholine : a new and selective
1315 antitumor drug. *Cancer Trmtnt Rev* 17:233–242.
- 1316 95. Croft SL, Snowdon D, Yardley V. 1996. The activities of four anticancer
1317 alkyllysophospholipids against *Leishmania donovani* , *Trypanosoma cruzi*
1318 and *Trypanosoma brucei*. *J Antimicrob Chemother* 38:1041–1047.
- 1319 96. Urbina JA. 2006. Mechanisms of action of lysophospholipid analogues

against trypanosomatid parasites. *Trans R Soc Trop Med Hyg* 100S:S9–S16.

97. Díaz Y de las MZ, Ambroggio EE, Fanani ML. 2020. Miltefosine inhibits the membrane remodeling caused by phospholipase action by changing membrane physical properties. *BBA - Biomembr* 183407.

98. Luque-Ortega J, Rivas L. 2007. Miltefosine (Hexadecylphosphocholine) Inhibits Cytochrome c Oxidase in *Leishmania donovani* Promastigotes □. *Antimicrob Agents Chemother* 51:1327–1332.

99. Bhattacharya A, Leprohon P, Bigot S, Padmanabhan PK, Mukherjee A, Roy G, Gingras H, Mestdagh A, Papadopoulou B, Ouellette M. 2019. Coupling chemical mutagenesis to next generation sequencing for the identification of drug resistance mutations in *Leishmania*. *Nat Commun* 10.

100. Borba-Santos LP, Gagini T, Ishida K, De Souza W, Rozental S. 2015. Miltefosine is active against *sporothrix brasiliensis* isolates with in vitro low susceptibility to amphotericin B or itraconazole. *J Med Microbiol* 64:415–422.

101. Brilhante RSN, Malaquias ÂDM, Caetano ÉP, De Souza Collares Maia Castelo-Branco D, De Lima RAC, De Farias Marques FJ, Silva NF, De Alencar LP, Monteiro AJ, De Camargo ZP, De Jesus Pinheiro Gomes Bandeira T, Rodrigues AM, De Aguiar Cordeiro R, Moreira JLB, Sidrim JJC, Rocha MFG. 2014. In vitro inhibitory effect of miltefosine against strains of *Histoplasma capsulatum* var. *capsulatum* and *Sporothrix* spp. *Med Mycol* 52:320–325.

102. Barreto TL, Rossato L, de Freitas ALD, Meis JF, Lopes LB, Colombo AL, Ishida K. 2020. Miltefosine as an alternative strategy in the treatment of the emerging fungus *Candida auris*. *Int J Antimicrob Agents* 56.

103. Imbert S, Palous M, Meyer I, Dannaoui E, Mazier D, Datry A, Fekkar A. 2014. In vitro combination of voriconazole and miltefosine against clinically relevant molds. *Antimicrob Agents Chemother* 58:6996–6998.

104. Rossi DCP, Spadari C de C, Nosanchuk JD, Taborda CP, Ishida K. 2017.

Miltefosine is fungicidal to *Paracoccidioides* spp. yeast cells but subinhibitory concentrations induce melanisation. *Int J Antimicrob Agents* 49:465–471.

105. Spadari C de C, Vila T, Rozental S, Ishida K. 2018. Miltefosine has a postantifungal effect and induces apoptosis in *Cryptococcus* yeasts. *Antimicrob Agents Chemother* 62.

106. Spadari C de C, de Bastiani FWM da S, Lopes LB, Ishida K. 2019. Alginate nanoparticles as non-toxic delivery system for miltefosine in the treatment of candidiasis and cryptococcosis. *Int J Nanomedicine* 14:5187–5199.

107. de Bastiani FWM da S, Spadari C de C, de Matos JKR, Salata GC, Lopes LB, Ishida K. 2020. Nanocarriers Provide Sustained Antifungal Activity for Amphotericin B and Miltefosine in the Topical Treatment of Murine Vaginal Candidiasis. *Front Microbiol* 10:1–9.

108. Vila TVM, Chaturvedi AK, Rozental S, Lopez-Ribot JL. 2015. In vitro activity of miltefosine against *Candida albicans* under planktonic and biofilm growth conditions and in vivo efficacy in a murine model of oral candidiasis. *Antimicrob Agents Chemother* 59:7611–7620.

109. Widmer F, Wright LC, Obando D, Handke R, Ganendren R, Ellis DH, Sorrell TC. 2006. Hexadecylphosphocholine (miltefosine) has broad-spectrum fungicidal activity and is efficacious in a mouse model of cryptococcosis. *Antimicrob Agents Chemother* 50:414–421.

110. Wu Y, Wu M, Gao J, Ying C. 2020. Antifungal Activity and Mode of Action of Miltefosine Against Clinical Isolates of *Candida krusei*. *Front Microbiol* 11:1–8.

111. Wu Y, Totten M, Memon W, Ying C, Zhang SX. 2020. In Vitro Antifungal Susceptibility of the Emerging Multidrug- Resistant Pathogen *Candida auris* to Miltefosine Alone and in Combination with Amphotericin B. *Antimicrob Agents Chemother* 64.

112. Dorlo TPC, Balasegaram M, Beijnen JH, de vries PJ. 2012. Miltefosine: A review of its pharmacology and therapeutic efficacy in the treatment of

1382 leishmaniasis. *J Antimicrob Chemother* 67:2576–2597.

1383 113. Zuo X, Djordjevic JT, Oei JB, Desmarini D, Schibeci SD, Jolliffe KA,
1384 Sorrell TC. 2011. Miltefosine induces apoptosis-like cell death in yeast via
1385 Cox9p in cytochrome c oxidase. *Mol Pharmacol* 80:476–485.

1386 114. Compain F, Botterel F, Sitterl E, Paugam A, Bougnoux ME, Dannaoui E.
1387 2015. In vitro activity of miltefosine in combination with voriconazole or
1388 amphotericin B against clinical isolates of *scedosporium* spp. *J Med*
1389 *Microbiol* 64:309–311.

1390 115. Maertens JA. 2004. History of the development of azole derivatives. *Clin*
1391 *Microbiol Infect Suppl* 10:1–10.

1392 116. Anderson TM, Clay MC, Cioffi AG, Diaz KA, Hisao GS, Tuttle MD,
1393 Nieuwkoop AJ, Comellas G, Maryum N, Wang S, Uno BE, Wildeman EL,
1394 Gonen T, Rienstra CM, Burke MD. 2014. amphotericin forms an
1395 extramembranous and fungicidal sterol sponge. *Nat Chem Biol* 10.

1396 117. Robbins N, Caplan T, Cowen LE. 2017. Molecular Evolution of Antifungal
1397 Drug Resistance. *Annu Rev of Microbiology* 71:753–775.

1398 118. Biswas C, Sorrell TC, Djordjevic JT, Zuo X, Jolliffe KA, Chen SCA. 2013.
1399 In vitro activity of miltefosine as a single agent and in combination with
1400 voriconazole or posaconazole against uncommon filamentous fungal
1401 pathogens. *J Antimicrob Chemother* 68:2842–2846.

1402 119. Dickson RC, Sumanasekera C, Lester RL. 2006. Functions and
1403 metabolism of sphingolipids in *Saccharomyces cerevisiae*. *Prog Lipid Res*
1404 45:447–465.

1405 120. Cheng J, Park T-S, Fischl AS, Ye XS. 2001. Cell Cycle Progression and
1406 Cell Polarity Require Sphingolipid Biosynthesis in *Aspergillus nidulans*.
1407 *Mol Cell Biol* 21:6198–6209.

1408 121. Heung LJ, Luberto C, Poeta M Del. 2006. Role of Sphingolipids in
1409 Microbial Pathogenesis. *Infect Immun* 74:28–39.

1410 122. Rella A, Farnoud AM, Poeta M Del. 2016. Plasma membrane lipids and
1411 their role in fungal virulence. *Prog Lipid Res* 61:63–72.

123. Cheng J, Park T, Chio L, Fischl AS, Ye XS. 2003. Induction of Apoptosis by Sphingoid Long-Chain Bases in *Aspergillus nidulans*. *Mol Cell Biol* 23:163–177.
124. Käfer E. 1977. Meiotic and Mitotic Recombination in *Aspergillus* and Its Chromosomal Aberrations, p. 33–131. *In* *Advances in Genetics*.
125. CLSI. 2008. Reference Method for Broth Dilution.
126. Gómez-Lopes A, Cuenca-estrella M, Mellado E, Rodríguez-Tudela JL. 2003. In vitro evaluation of combination of terbinafine with itraconazole or amphotericin B against Zygomycota. *Diagn Microbiol Infect Dis* 45:199–202.
127. Colot H V, Park G, Turner GE, Ringelberg C, Crew CM, Litvinkova L, Weiss RL, Borkovich KA, Dunlap JC. 2006. A high-throughput gene knockout procedure for *Neurospora* reveals functions for multiple transcription factors. *PNAS* 103.
128. Semighini CP, Marins M, Goldman MHS, Goldman GH. 2002. Quantitative Analysis of the Relative Transcript Levels of ABC Transporter Atr Genes in *Aspergillus nidulans* by Real-Time Reverse Transcription-PCR Assay. *Appl Environ Microbiol* 68:1351–1357.
129. Fan X, Lamarre-vincent N, Wang Q, Struhl K. 2008. Extensive chromatin fragmentation improves enrichment of protein binding sites in chromatin immunoprecipitation experiments. *Nucleic Acids Res* 36:1–7.
130. Wong KH, Struhl K. 2011. The Cyc8 – Tup1 complex inhibits transcription primarily by masking the activation domain of the recruiting protein. *Genes Dev* 25:2525–2539.
131. Langmead B, Trapnell C, Pop M, Salzberg SL. 2009. Ultrafast and memory-efficient alignment of short DNA sequences to the human genome. *Genome Biol* 10.
132. Singh A, Poeta M Del. 2016. Sphingolipidomics : An Important Mechanistic Tool for Studying Fungal Pathogens. *Front Microbiol* 7:1–14.
133. Singh A, Mackenzie A, Girnun G, Poeta M Del. 2017. Analysis of

- sphingolipids , sterols , and phospholipids in human pathogenic
Cryptococcus strains. J Lipid Res 58:2017–2036.
134. Mandala SM, Thornton RA, Frommer BR, Curotto JE, Rozdilsky W, Kurtz
MB, Giacobbe RA, Bills GF, Cabello MA, Martin I, Pelaez F, Harris GH.
1995. The Discovery of Australifungin , a Novel Inhibitor of Sphinganine
TV-Acyltransferase from *Sporormiella australis* Producing Organism ,
Fermentation , Isolation , and Biological Activity. J Antibiot (Tokyo) 48.
135. Bligh E, Dyer W. 1959. A rapid method of total lipid extraction and
purification. Can J Biochem Physiol 37.
136. Clarke NG, Dawson RM. 1981. Alkaline O-N-transacylation: A new
method for the quantitative deacylation of phospholipids Neville. Biochem
J 195:301–306.
137. Jemel S, Guillot J, Kallel K, Botterel F, Dannaoui E. 2020. *Galleria*
mellonella for the evaluation of antifungal efficacy against medically
important fungi, a narrative review. Microorganisms 8.
138. Fernandes C, Fonseca F, Goldman G, Pereira M, Kurtenbach E. 2017. A
Reliable Assay to Evaluate the Virulence of *Aspergillus nidulans* Using
the Alternative Animal Model *Galleria mellonella* (Lepidoptera). Bio-
Protocol 7:1–13.
139. Heel RC, Morton P, Brogden RN, Speight TM, Avery GS. 1979.
Econazole: A Review of its Antifungal Activity and Therapeutic Efficacy.
Drugs 18:177–201.
140. Tavakkoli A, Johnston TP, Sahebkar A. 2020. Antifungal effects of statins.
Pharmacol Ther 208:107483.
141. Su Z, Martin R, Cox BF, Gintant G. 2004. Mesoridazine: An open-channel
blocker of human ether-a-go-go-related gene K⁺ channel. J Mol Cell
Cardiol 36:151–160.
142. Orihata M, Sarna SK. 1994. Contractile mechanisms of action of
gastroprokinetic agents: Cisapride, metoclopramide, and domperidone.
Am J Physiol - Gastrointest Liver Physiol 266:665–676.

- 1472 143. Del Rosso JQ, Kircik LH. 2013. Optimizing topical antifungal therapy for
1473 superficial cutaneous fungal infections: focus on topical naftifine for
1474 cutaneous dermatophytosis. *J drugs dermatology* 12:165–171.
- 1475 144. Pollak EB, Parmar M. 2021. IndinavirStatPearls.
- 1476 145. Davies R, Gomez H, Irvin J, Walker J. 1984. An overview of the clinical
1477 pharmacology of enalapril. *Br J Clin Pharmacol* 18:215S-229S.
- 1478 146. Franzyk H, Christensen SB. 2021. Targeting Toxins toward Tumors.
1479 *Molecules* 26.
- 1480 147. Gupta YK, Gupta M, Aneja S, Kohli K. 2004. Current Drug Therapy of
1481 Protozoal Diarrhoea. *Indian J Pediatr* 71:55–58.
- 1482 148. Roatt BM, de Oliveira Cardoso JM, De Brito RCF, Coura-Vital W, de
1483 Oliveira Aguiar-Soares RD, Reis AB. 2020. Recent advances and new
1484 strategies on leishmaniasis treatment. *Appl Microbiol Biotechnol*
1485 104:8965–8977.

1486 1487 **Figure Legends**

1488
1489 **Figure 1. Miltefosine is a potential new anti-aspergillosis compound and**
1490 **shows its interaction with the sphingolipid inhibitor myriocin.** (A). Screening
1491 of chemical libraries reveals potential new anti-aspergilosis compounds. (B)
1492 Interaction between miltefosine and Posaconazole. (C) Interaction between
1493 miltefosine and voriconazole. (D) Interaction between miltefosine and
1494 amphotericin B. (E) Interaction between miltefosine and caspofungin. (F)
1495 Interaction between miltefosine and myriocin

1496
1497 **Figure 2. Radial growth of transcription factor (TF) null mutants in presence**
1498 **of miltefosine.** (A) A total of 1×10^5 conidia of each specie was inoculated on
1499 MM supplemented or not with increasing concentration of miltefosine. Plates
1500 were incubated for 3 days at 37°C. (B) Quantification of the results obtained in
1501 (A). For each strain three independent experiments were realized and the graphic
1502 shows the mean $\pm$ standard deviations.

Figure 3. Molecular characterization of *rmiA*. (A) Growth phenotypes of the wild-type, $\Delta rmiA$ and $\Delta rmiA::rmiA^+$ strains grown for 3 days on solid MM supplemented with increasing concentrations of miltefosine. (B) Graphical quantification of fungal growth presented in (A). The results are the average of three repetitions $\pm$ standard deviation of three repetitions. (C) RmiA:GFP translocates to the nucleus under exposure to miltefosine. (D) Graphical quantification of RmiA:GFP location shown in (C). The results are the average of three repetitions $\pm$ standard deviation of 30 germlings for each repetition. (E) Western blotting assay showing the RmiA:HA expression after 0, 4 and 8h of incubation with 12.5 μ g/mL miltefosine. Anti-HA antibody was used to detect the recombinant protein. Anti-actin antibody was used as a loading control. Statistical analysis was performed using one-tailed, paired *t* tests for comparisons to the control condition (*, *p* < 0.05; ***, *p* < 0.001;)

Figure 4. There is increased mitochondrial fragmentation and cell death when *A. fumigatus* $\Delta rmiA$ is exposed to miltefosine. (A) Mitochondrial morphology revealed by mitotracker in the wild-type, $\Delta rmiA$, and $\Delta rmiA::rmiA^+$ strains. (B) Quantification of the mitochondrial fragmentation in the absence (control) and presence of miltefosine. (C) Quantification of PI⁺ (propidium iodide) germlings in the absence (control) and presence of miltefosine. The results are the average of three repetitions $\pm$ standard deviation of 30 germlings for each repetition.

Figure 5. The fluorescent miltefosine analogue MT-11C-BDP is localized in the mitochondria. (A) and (B) *A. fumigatus* germlings (16 h growth in MM) were exposed for 5 minutes to μ g/mL of MT-11C-BDP. Germlings were stained with MitoTracker Deep RedTM FM.

Figure 6. Transcriptional profiling of *A. fumigatus* wild-type and $\Delta rmiA$ exposed to miltefosine. (A) FunCat categorization of differently expressed genes (DEGs) up- and downregulated in the wild-type strain exposed to miltefosine in comparison to the wild-type strain grown in VMM (control). (B) FunCat analysis of DEGs downregulated in the $\Delta rmiA$ strain under miltefosine

exposure in comparison to the $\Delta rmiA$ grown in VMM. (C) Heat map of log₂ fold change (Log₂FC) of DEGs as determined by RNAseq. Log₂FC values are based on comparisons between (i) wild-type strain exposed to miltefosine *versus* wild-type strain in grown in MM (control); (ii) $\Delta rmiA$ grown in VMM (control) *versus* wild-type grown in VMM (control); (iii) $\Delta rmiA$ strain exposed to miltefosine *versus* wild-type strain under miltefosine treatment. Hierarchical clustering was performed in Multiple Experiment Viewer (MeV) (<http://mev.tm4.org/>), using Pearson correlation with complete linkage clustering. Heat map scale and gene identities are shown. (D) Validation of RNA -seq data. Expression of three genes as determined by qRT -PCR after 0 and 30 minutes of exposition to 3µg/mL of miltefosine. Gene expression values were normalized by the expression of β -tubulin. Standard deviations are shown for biological triplicates.

Figure 7. Chromatin Immunoprecipitation coupled to next generation sequencing (ChIP-Seq) of the wild-type and the $\Delta rmiA$ strains exposed to miltefosine. (A) ChIP-Seq Integrative Genomics Viewer (IGV; <http://software.broadinstitute.org/software/igv/download>) screenshot for promoter regions of genes that bound to RmiA:3xHA when grown for 24 h in VMM or after the addition of 12.5 µg/mL miltefosine for 30 min. (B) Heat map of the ChIP-seq results for 6 genes showing the fold enrichment of RmiA binding after 0 and 30 minutes of exposure to 12.5 µg/mL of miltefosine and the RNAseq results for the same 6 genes in the WT and $\Delta rmiA$ strains after exposure to 3µg/mL during 30 minutes. (C) MEME (Multiple EM for Motif Elicitation)-ChIP analysis of the 500 bp region surrounding the peaks identified in the ChIP-seq analysis.

Figure 8. Deletion of *rmiA* leads to an overall reduction of sphingolipids biosynthesis in *A. fumigatus*. (A) The wild-type and $\Delta rmiA$ strains were grown in liquid VMM 16h and transferred to RPMI medium supplemented (or not) with 3 µg/mL miltefosine for additional 4h, the sphingolipids were extracted and measured by mass spectrometry. Heat maps labeled surrounded by boxes with gray borders represents the intermediates of SL biosynthetic pathway heat maps surrounded by boxes with green borders represents the intermediates from the neutral branching while heat maps surrounded by boxes with yellow borders

represents the intermediates from the acidic branch of SL biosynthetic pathway. Heat maps show the values obtained by the ratio VMM/RPMI. Experiments were performed by using three independent biological experiments and the results are the average of them. Statistical analysis was performed using Student's t-test ($p < 0.05$). (B) Diagram showing the different genes involved in the sphingolipids biosynthesis. Expression levels of genes encoding enzymes involved in the sphingolipids biosynthesis were selected from the RNAseq analysis. DHS, dihydrosphingosine; DHS-1P, dihydrosphingosine 1-phosphate; DHC, dihydroceramide; Cer, ceramide; GlcCer, glucosylceramide; OH-Cer, hydroxy-ceramide; PHS, phytosphingosine; PHS-1P, phytosphingosine 1-phosphate; PCer, phytoceramide; OH-PCer, hydroxy-phytoceramide; IPC, inositolphosphoryl ceramide.

Supplemental material

Supplementary Figure S1. The deletion of *rmIA* causes no growth impact in the presence of different stress conditions. Strains were grown from 10^5 spores for 5 days at 37°C on minimal media (MM) supplemented or not with (A) CaCl_2 , (B) calcofluor white (CFW), (C) sorbitol, (D) NaCl, (E) menadione and (F) variable temperature. The results are expressed as the average of radial diameter of the treatment divided by the radial diameter of the control of three independent experiments $\pm$ SD. Standard deviations present the average of three independent biological repetitions.

Supplementary Figure S2. Construction of *rmIA::3xHA* and *rmIA::GFP* strains. Both strains were constructed in the $\Delta rmIA$ background and confirmed by PCR using *rmIA* pRS426 3R (P5) and *rmIA* 1500UP ext F (P6) primers. The *rmIA::3xHA* (A) and *rmIA::GFP* (B) are functional, do not present growth defects and restored the miltefosine sensitivity of the $\Delta rmIA$ null mutant.

Supplementary Table S1. Genes differentially expressed in the wild-type exposed to miltefosine.

Supplementary Table S2. Genes differentially expressed in the $\Delta rmIA$ mutant compared to the wild-type exposed to miltefosine.

1603 **Supplementary Table S3.** Genes identified in the RmiA ChIP-seq.

1604 **Supplementary Table S4.** Strains used in this work.

1605 **Supplementary Table S5.** List of primers used in this work

1606

1607

1608

1609

1610

1611

1612

1613

1614

Table 1. MIC values for NIH Clinical collection and Pathogen box compounds against *A. fumigatus*

	MIC (μM)	Description	Mode of Action	References
Econazole nitrate	12.5	broad-spectrum antimycotic agent	Inhibits ergosterol biosynthesis	(139)
Fluvastatin	25	statin drug class used for hypercholesterolemia treatment; the drug has demonstrated antifungal activity against some fungal species	blocks ergosterol biosynthesis by inhibition of farnesyl pyrophosphate production	(140)
Mesoridazine	3.12	piperidine neuroleptic drug used for the treatment of schizophrenia, organic brain disorders, alcoholism, and psychoneuroses	acts indirectly on reticular formation, whereby neuronal activity into reticular formation is reduced without affecting its intrinsic ability to activate the cerebral cortex	(141)
Cisapride	1.56	gastroprokinetic agent, a drug that increases motility in the upper gastrointestinal tract	Parasympathomimetic acting as a serotonin 5-HT ₄ agonist	(142)
Oxiconazole nitrate	25	salt form of oxiconazole with antifungal activity	Inhibits ergosterol biosynthesis	(143)
Indinavir sulphate	6.25	antiretroviral protease inhibitor used in the therapy and prevention of human immunodeficiency virus (HIV) infection and the acquired immunodeficiency syndrome (AIDS)	Protease inhibitor	(144)
Enalaprilat	25	Used in the treatment of hypertension	Angiotensin-converting enzyme inhibitor	(145)

Vincristine sulfate	25	Used in cancer chemotherapy	Inhibits microtubule formation in mitotic spindle salt of a natural alkaloid with antimitotic and antineoplastic activities	(146)
Iodoquinol	2	antiprotozoal agent used as an amebicide drug	Unknown	(147)
Miltefosine	10	antiprotozoal, bactericidal and antifungal agent	Unknow	(148).

Table 2. Minimum inhibitory concentration (MIC, concentration in $\mu\text{g}/\mu\text{l}$) of *A. fumigatus* clinical isolates in the presence of different antifungals drugs

Strains	Itraconazole	Posaconazole	Voriconazole	Amphotericin B	Miltefosine
CEA17	2	2	1	0.5	4
F16134	>8	>8	4	0.25	4
F14946	>8	8	8	0.25	4
CYP15-117	>8	2	2	0.5	4
CYP15-147	>8	2	8	1	4
20089320	>8	4	4	1	4
CYP15-75	8	4	8	0.5	4
CYP15-91	8	1	2	1	4
CYP15-93	8	1	2	0.5	4
CYP15-106	8	2	1	1	4
CYP15-115	8	0.5	0.5	0.25	4
17993925	8	2	4	1	4
CYP15-109	4	1	>8	0.5	4
IF1S-F4	4	1	1	0.5	4
IFM59056	4	1	0.125	0.5	4
ISFT-021	2	1	0.25	1	4
IFM61407	2	2	0.125	0.5	4
MO68507	1	1	0.25	0.5	4
MO54056	1	1	0.125	0.5	4
IFM59056	1	1	0.125	0.5	4

Drug (Concentration)	% of growth
Control	~95
econazole nitrate (12.5μM)	~5
fluvastatin (25μM)	~1
mesoridazine (3.12μM)	~2
cisapride (1.56μM)	~0
oxiconazole nitrate (25μM)	~5
indinavir sulphate (6.25μM)	~0
vincristine sulphate (25μM)	~18
enalaprilat (25μM)	~1
Iodoquinol (2μM)	~21
Miltefosine (10μM)	~0

Voriconazole (µg/mL)	Mititefosine (µg/mL)
0.0	1.0
0.05	1.0
0.1	1.0
0.15	2.0
0.25	2.0
0.5	0.0

C.

D.

E.

F.

Drug	Myriocin FICI (μg/mL)							Mean
	2.0	4.0	8.0	16.0	32.0	64.0	128	
Miltefosine	1.1	1.2	1.5	2.0	3.0	5.0**	9.0**	3.2

A.

Wild-type

$\Delta rmiA$

$\Delta rmiA::rmiA^+$

B.

Mitochondrial fragmentation (%)

C.

PI⁺ germlings (%)

A. WT miltefosine x WT control

B. Δ ArmIA miltefosine x Wild-type miltefosine

C.

D.

B.

C.

Motif found
E-value: 0.038
Known or similar motifs:
SKO1 (MA0382.1)
TOD6 (MA0350.1)

Motif found
E-value: 0.05
Known or similar motifs:
YPR196W (MA0437.1)
HAL9 (MA0311.1)

A.

B.

A.

B.

C.